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CHAPTER 1: INTRODUCTION 
1.1 Obesity and Cancer  
1.1a Obesity: A Global Pandemic  
Obesity is “ a condition characterized by the excessive accumulation and storage of 
fat in the body.” [1, 2]. This excess storage of fat is due to an imbalance between caloric 
intake and energy expenditure, influenced by both modifiable and genetic risk factors 
[3]. Obesity is clinically defined on a population-based level by body mass index (BMI), 
an index that accounts for a patient’s height and weight (kg/m2). Patients with a BMI 
greater than or equal to 30 are considered clinically obese, and between 25-30 are 
considered overweight [3]. This system of clinically defining obese patients has been 
used in research to uncover many disease associated risks factors [4-11].  
In the last 25 years, the prevalence of obesity has doubled worldwide, leading to 
nearly one-third of adults being considered overweight or obese in 70 countries [12]. 
The escalating obesity pandemic is particularly concerning because obesity is a known 
risk factor for an array of chronic, debilitating or life-threatening diseases [4-11]; such as 
rheumatoid arthritis, type 2 diabetes mellitus, cardiovascular disease, and cancer. 
Underpinning the risk association between obesity and these diseases is the 
accumulation of excess adipose tissue that elicits an aberrant innate immune response 
causing local and systemic, chronic inflammation [13-19]. This activation of pro-
inflammatory signaling is associated with an increase in infiltrated immune cells and 
shift in phenotype within the adipose tissue. Importantly M2 polarized macrophages 
contribute significantly to the production of pro-inflammatory cytokines including 
interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in the adipose tissue of 
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obese individuals [20, 21], which can in turn lead to the aberrant production of free 
radicals, including reactive oxygen species (ROS), both of which are hallmarks of 
obesity [22]. 
1.1b Obesity and Cancer Risk  
Cancer is a disease defined by an abnormal growth of cells within an organ, 
leading to the formation of a tumor or mass, which can invade surrounding tissues or 
colonize distant tissues in a process referred to as metastasis; the principal cause of a 
cancer-related death. Presently, cancer is the second leading cause of death in the US, 
and recent reports have raised awareness that the number of cancer cases associated 
with obesity is substantial and increasing [23-25], and obesity-related cancers in 
younger female patients are also more frequently occurring [12, 25]. 
1.1c Obesity-associated TNBC Risk  
Contributing to this burden is the association between obesity and breast cancer 
(BCa), the most common cancer in women [26]. However, most epidemiological studies 
to date, which have associated risk of obesity with BCa, failed to stratify patients by 
histological subtype [27]. In recent years there have been a series of epidemiological 
studies published that assess risk in patient populations stratified by histological 
subtype, including human epidermal growth factor receptor 2 (HER2) positivity in their 
analysis, which has uncovered an association in pre-menopausal women between 
obesity (BMI >30) and hormone/HER2 receptor negative cancer, also known as Triple 
Negative Breast Cancer (TNBC) [4-10, 28-33]. These studies report that obesity is a risk 
factor for TNBC diagnosis and worse cancer-associated outcomes [4-10, 28-32].  
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Poorer outcomes associated with TNBC, are in part due to the lack of therapeutic 
options available. As TNBC tumor cancer cells lack expression of estrogen receptor 
alpha (ERα), progesterone receptor (PR), and the HER2 oncogene, none of the 
currently available molecularly targeted therapeutics, used in the treatment of other BCa 
subsets, are used to treat TNBC patients. Overall, TNBC patients tend to have a poorer 
prognosis, including higher probability of both metastasis and recurrence, after initial 
response to chemotherapeutic treatment [34-40]. Understanding how obesity might 
influence the biology of this BCa subtype also has the potential to uncover novel and 
more context dependent drug targets.  
Pre-menopausal African American (AA) women, whom are more likely to develop 
TNBC [38, 41-45], are also more likely to be obese in the US [21, 46]. Moreover, there 
is evidence that AA women with TNBC have worse overall survival than European 
American (EA) women [21]. Studying the effects of obesity on tumor biology could be an 
important way to improve our understanding of racial disparities in TNBC incidence and 
outcomes, which persist.  
1.1d Mechanisms Driving Obesity-associated TNBC 
The association between obesity and diagnosis of ERα positive, hormone-
dependent BCa in post-menopausal patients, was recognized early [47]. A prevailing 
idea regarding the molecular mechanism is that ERα-positive cancer in post-
menopausal women is fueled by estrogens that are synthesized by adipose tissue in 
response to inflammatory signaling factors [48]. TNBCs are hormone-independent, thus 
the past prevailing idea regarding adipose tissue derived estrogens, as a mechanism 
driving obesity-associated risk, is irrelevant.  
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Several hormone-independent features of obesity have been associated with 
promoting obesity-associated cancers and TNBC, including hyperinsulinemia, fatty acid 
metabolism, and circulating and local production of cytokines and adipokines, which 
results in increased ROS production [18, 19, 21]. Some important signaling factors 
include insulin, glucose, leptin, IL-6 and adiponectin. Many of these signaling factors 
and their requisite pathways have been studied extensively in cancer, and act as tumor 
growth promoters	 [19, 21]. Leptin, insulin signaling and others have also been linked to 
cancer stem cell-like cells (CSCs), and expression of pluripotency transcription factors 
[49-57]. Whether, the mechanism downstream of these signaling factors, which actually 
promotes CSCs, are related to obesity-associated risk, remains unclear.  
1.2 CSCs 
1.2a Defining CSCs 
CSCs represent a small subpopulation of less differentiated cancer cells found 
within TNBC tumors, as well as patient-derived cell cultures, which may represent as 
little as 0.05-1% of total cells within a tumor [58-81]. The CSC sub-population of cells 
have unique characteristics, as compared to other cells within a tumor, including their 
ability to self-renew, asymmetrically divide, initiate tumors in mice, resist effects of drug 
treatment, and remain quiescent [63-70, 73-78, 80, 81]. Normal adult stem cells, 
including mammary stem cells, have some of these characteristics, such as asymmetric 
division, self-renewal capacity, and quiescence. However, CSCs are distinctly tumor 
cells, and the origin of CSCs remains unclear [82, 83]. Though how adult stem cells and 
CSCs are regulated could be very similar [83].  
1.2b Role in Cancer  
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One of the major rate-limiting steps in the formation of a distant metastasis is 
colonization of disseminated tumor cells, as less than 0.1% of cells may actually seed 
and subsequently have the ability to form macrometastases in a non-native tissue or 
organ [84]. Several studies have shown that disseminated BCa cells capable of 
overcoming these odds tend to have characteristics of CSCs [63-66], and CSC 
enrichment is associated with clinical cancer metastasis [58-62, 64, 67-71] and also 
obesity [49-57]. Moreover, there is an overwhelming body of evidence showing that 
obesity is associated with features linked to worse outcomes including: higher grade 
tumors, distant metastasis, shorter disease-free survival and greater risk of mortality 
[85], with metastasis being the primary complication associated with cancer-related 
death. Finally, TNBC patients have also been shown to have higher abundance of 
CSCs, linked with worse outcomes [58-62], emphasizing the importance of studying 
CSCs in this particular subtype of BCa. 
1.2c Experimental Models for Studying CSCs 
CSCs can be identified and studied in vitro using an enrichment assay, such as a 
mammosphere or prostasphere assay. In this assay, bulk populations of cells are plated 
in non-adherent, serum-free conditions, and CSCs are selected for by growing over a 
set period of time [57, 86, 87]. This assay measures self-renewal capacity by providing 
a crude estimate of the number of cells in a cultured population, which have the 
capacity to survive and self-renew.  
Cell surface markers are used to sort and identify CSCs via flow cytometry, and 
further test the molecular characteristics and drug sensitivity of CSCs in vitro, and are 
also used to identify CSCs in patient tumors [67, 88-91].  However, defined sets of cell 
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surface markers have not yet been established for TNBC, and the percentage of cells 
deemed stem-like are conflicting between these studies. These assays measure the 
presence of CSCs in culture and in tumor tissues, or their self-renewal capacity.  
Given that CSCs are known to have metastatic potential and are associated with 
clinical cancer metastasis [64, 67-71], their ability to form tumors in vivo is an important 
defining feature. Thus the current gold standard for studying the presence of CSCs in a 
bulk population is by performing a tumor propagating experiment [87, 90, 92], first 
described in 1997 in acute myeloid leukemia [93]. Examining the tumorigenicity of a 
bulk population of cells at low cell titers, after inoculation in an immune compromised 
mouse tumor model, is performed to test for presence of CSCs; as it has been shown 
that CSCs are characteristically tumor initiating. Using this assay, cells can be 
genetically manipulated or treated with drugs before or after inoculation in mice, in order 
to test changes in tumorigenicity compared to a known control group.   
1.2d Clinical Relevance of Studying CSCs 
Targeting CSCs is thought to be crucial in overcoming resistance to 
chemotherapy, and preventing further development of metastatic disease. As described 
above, it is well established that the process of metastasis occurs early after 
tumorigenesis, and that the rate-limiting step to the formation of overt metastasis, is the 
ability of a circulating tumor cell to seed at a distant site; of which CSCs play a distinct 
role. Therapeutic targeting of the CSC population therefore has the potential to inhibit 
further growth of seeded tumor cells at metastatic sites. TNBC patients tend to have 
positive initial responses to chemotherapeutic treatment, but have higher probability of 
both metastasis and recurrence, contributing to poorer outcomes [34-40]. Identification 
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of targetable CSC driver genes will be crucial for improving TNBC outcomes, by 
preventing metastatic tumor growth.  
1.2e ROS and CSCs   
One well understood characteristic of obesity is systemic induction of chronic 
inflammation [94, 95]; specifically the accumulation of adipose tissue in obese patients 
triggers innate immune responses, which in turn leads to aberrant production of ROS, 
as stated above [22, 96-99].  
ROS plays an important role in normal stem cell biology, impacting self-renewal 
and differentiation in a dose-dependent manner. Stem cells are also more sensitive to 
ROS levels than their asymmetrically produced progeny, and have developed 
mechanisms for surviving in the presence of ROS [100]. Alterations in ROS production 
are also a known hallmark of cancer cells, of which upregulated ROS production has 
been shown to promote CSCs, and trigger alterations in antioxidant enzyme activity	
[100].  
Antioxidants, which maintain the cellular balance of ROS to prevent damage and 
maintain necessary redox signaling, have less intrinsic activity in obese individuals 
[101], whom have enrichment of CSCs. In particular, catalase, an H2O2 neutralizing 
enzyme, has less activity in obese patients [20]. Our lab has shown that treatment with 
either genetically engineered catalase or (-) epicatechin, which reduces cellular H2O2 
and thus perturb the redox state of the cell, inhibits survival and self-renewal capacity of 
TNBC cell line-derived CSCs	[57].  
Findings, including ours, also demonstrate that ROS is an important driver of 
TNBC CSCs	 [57, 102] and malignant BCa cell transformation [103]. For example, 
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normal mammary epithelial cells have nearly undetectable levels of ROS in culture, 
versus HER2 expressing cells, which have higher ROS levels and induced HIF1α 
signaling	 [103]. Moreover, we find that TNBC cells have higher intracellular levels of 
ROS, compared to normal breast epithelial cells [57]. 
ROS species, such as H2O2, can act as signaling molecules to modulate 
homeostatic redox levels by impacting protein function and gene expression in normal 
stem cells, which are particularly sensitive to oxidative stress	 [100]. In our studies, in a 
time course microarray analysis, comparing antioxidant treated versus untreated TNBC 
cells, we identified a gene whose expression was ROS-dependent and crucial for CSC 
maintenance and expansion in TNBC cell cultures [57]. This gene was an epigenetic 
reader protein called methyl-CpG-binding domain protein 2 (MBD2), specifically the 
MBD2 mRNA transcript variant 2 (MBD2_v2). Further analysis of this gene in TNBC cell 
lines revealed that MBD2_v2 expression was higher in CSCs in cell culture, as 
compared to bulk cancer cells, and that overexpression of MBD2_v2 was capable of 
promoting CSC formation in in vitro sphere formation assays. These data suggested 
that ROS-dependent expression of MBD2_v2 was important for promoting TNBC CSC 
self-renewal capacity in vitro.  
1.3 MBD2 
1.3a MBD2 Splice Variants 
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MBD2 was first identified in 1998 by Hendrich and Bird, as part of a nuclear 
family of methyl binding domain (MBD) containing proteins [104]. Post-transcriptionally, 
MBD2 mRNA is alternatively spliced yielding two mRNA spliced variants, which differ in 
the C-terminal end of each resulting protein  (Fig. 1) [104]. The longest MBD2 gene 
product, MBD2 transcript variant 1 (MBD2_v1), has 3 main domains, an N-terminal 
glycine/arginine rich region, an internal MBD, and a c-terminal transcriptional repressor 
domain (TRD) encoded by exons 4-7. MBD2 binds methylated CpG sites through an 
electrostatic interaction, where two arginine residues within the MBD form hydrogen 
bonds with guanines surrounding methylated cytosines (5-mc), which stabilizes the 
central β-sheet within that region and leaves the outer N-terminal and C-terminal 
domains mobile [105, 106]. An intrinsically disordered region also exists within the TRD, 
which kinetically enhances the affinity of MBD2 for methylated CpG residues [104, 107].  
After binding a methylated CpG site, MBD2 recruits the nucleosome remodeling 
deacetylase (NURD) complex through its C-terminal TRD domain to repress RNA 
transcription at sites of dense 5-mc [108-111]. MBD2_v1 is classically known to bind 
Figure 1. Graphical representation of MBD2 gene coding exons 
(E1-E8), along with structural domains of alternatively spliced mRNA 
variant species 1 and 2 derived from the MBD2 gene transcript and 
their translated protein lengths. MBD=methyl binding domain; 




hypermethylated CpG sites in DNA promoter regions to inhibit RNA transcription of 
target genes, which is also thought to promote differentiation in the context of human 
pluripotent stem cells  (hPSCs) [104, 107, 112]. However, studies have shown that 
knockdown (KD) of MBD2 gene products, non-specifically targeting both transcript 
variants, leads to both up and downregulation of global gene expression; and more 
intriguingly MBD2 is less frequently bound to DNA regions near epigenetic marks 
associated with active transcription [108-111], which directly opposes known repressive 
functions.  
MBD2_v2, also known as the testis-specific isoform, is spliced by the serine and 
arginine rich splicing factor 2 (SRSF2) in hPSCs [112]. Studies in hPSCs show that the 
SRSF2 splicing factor binds MBD2 pre-mRNA at the exon 2-3 junction, and promotes 
alternative splicing of the MBD2_v2 mRNA [112]. MBD2_v2 is particularly unusual as it 
lacks the TRD, but retains a short unique exon of unknown function at its c-terminus. 
This structural difference renders MBD2_v2 putatively unable to bind and recruit 
transcriptional repressors, such as the NURD complex.  
MBD2 has been shown to bind several pluripotency transcription factor 
promoters including the POU class 5 homeobox 1 (OCT4), Nanog homeobox (NANOG), 
and SRY-box 2 (SOX2) genes in hPSCs, which were actively being transcribed [104, 
112]. This interaction has been shown to be important in maintaining pluripotency of 
hPSCs [112].  
1.3b MBD2_v2 Function  
The normal molecular function of the MBD2_v2 splice variant in any type of 
terminally differentiated or adult progenitor cell is largely unknown. The only known 
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function of MBD2_v2 is in promoting pluripotency of hPSCs and promoting 
reprogramming of induced pluripotent stem cells [112]; as well as in our study which 
shows that MBD2_v2 plays a distinct functional role in maintaining self-renewal capacity 
of TNBC CSCs [57].   
In TNBC whole cell lysates we have found that MBD2_v1 protein and mRNA are 
expressed at a significantly higher level than MBD2_v2 [57]. We also find that 
expression of MBD2_v2 is exclusively higher than MBD2_v1 in CSCs, versus bulk 
TNBC cell populations [57]. Together these data suggests that MBD2_v2 expression is 
functionally important in the TNBC CSC sub-population.  
1.4 Relationship between TNBC and Obesity-associated PCa  
Although women appear to bear more of the burden of cancers attributable to 
obesity, men are not invulnerable. Prostate Cancer (PCa), which is the second leading 
cause of cancer-related death among men, similar to TNBC has also been shown to be 
associated with obesity-related risk and high-grade PCa disease [113-116].  
High-grade PCa and TNBC are similar in that they disparately impact AAs. AA 
women tend to have higher incidence of TNBC [38, 41-45]. Similarly AA men (AAM) 
have been shown to have both a higher rate of PCa incidence and a two-fold to five-fold 
greater risk of PCa-related mortality, compared to EA men (EAM) [117]. These 
disparities could reflect higher rates of obesity reported in AA populations [46]. 
Obesity-associated risk factors, including higher fat content diets, higher BMI 
[118, 119], and higher rates of hypertension are reported in AA PCa patients. However, 
the relationship between race and disease burden remains to be fully understood, and 
the cause is likely multifaceted, including undetermined contributions from ancestry 
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genetics and life-style risk factors [120-124]. Though improvements in PCa detection, 
access to care, and survival across all demographics have been made, PCa race 
disparities still continue [117, 125, 126], and AAM diagnosed with low-risk PCa are 
more likely to intrinsically harbor high risk disease [127]. 
We have shown that PCa tumors from AAM have upregulation of inflammatory-
related genes [128], such as IL-6 and nuclear factor kappa B (NFκB), both of which 
have been associated with obesity-related cancers [19]. Given that pro-inflammatory 
signaling is an important feature of obesity [13-19], we hypothesized that these data 
might reflect an underlying molecular difference in an obese phenotype, between AAM 
and EAM.  Determining how obesity and inflammatory-related signaling affects the 
molecular biology of PCa could reveal important molecular targets for high-grade AAM 
PCa patients, whom currently are limited in their therapeutic options.  
In this study, we extend our work from TNBC to PCa, given the similarities in 
racial disparities and obesity-related risk, and demonstrate the importance of MBD2_v2 
in driving PCa CSCs, linked to pro-inflammatory IL-6 signaling.  
1.5 Hypothesis  
 Obesity represents a distinct health-related state, which disproportionately 
impacts TNBC and high-risk PCa patient populations. The escalating obesity pandemic 
is particularly concerning because obesity is a known risk factor for an array of chronic, 
debilitating or life-threatening diseases [4-11]. Obesity impacts health by generating 
significant redox imbalance driven by pro-inflammatory cytokine signaling.  
The central hypothesis of my dissertation work is that ROS-dependent MBD2_v2 
expression is a key molecular feature driving TNBC and high-risk PCa incidence and 
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recurrence due to its ability to maintain and promote expansion of tumor-initiating CSCs. 
Considering that obesity is coupled with inflammation [129, 130], we also hypothesize 
that obesity might fuel this mechanism to increase MBD2_v2 expression and in turn 
enhance the tumor-initiating CSC phenotype (Fig. 2).  
This study sought to better understand how MBD2_v2 is regulated in CSCs and 
whether obesity or obesity-related inflammatory signaling plays a role in increasing 
expression of MBD2_v2 in TNBC and PCa cells to promote the CSC phenotype, which 
could explain some of the racial disparities that currently exist in these patient 
populations.
Figure 2. Graphical representation of hypothesis, describing that obesity, which 
is associated with ROS production promoted by chronic inflammation, drives 
TNBC CSCs through upregulation of MBD2_v2 expression.  
Obesity 
•  Risk factor for 
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CHAPTER 2: OBESITY PROMOTES EXPRESSION OF MBD2_V2 IN TUMO-
INITATING TNBC CELLS  
 The data presented in this chapter were published on January 19th, 2019 in the 
journal Molecular Oncology [131].  
 
2.1 Preface 
 All mouse model experiments were performed in collaboration with Dr. Lisa 
Polin at the Karmanos Cancer Institute (KCI) Animal Model and Therapeutics 
Evaluation Core facility. Dr. Kristen S. Purrington at the KCI Population Sciences 
Department was generous in providing the human microarray data. Statistical 
analyses were performed in collaboration with Dr. Gregory Dyson at the KCI 
Biostatistics core. 
2.2 Introduction 
 In the last 25 years the prevalence of obesity has doubled in 70 countries, 
including the United States, and nearly one-third of adults worldwide are now 
overweight or obese [12]. The rising obesity pandemic is decidedly concerning because 
obesity is a known risk factor for an array of chronic, debilitating or life-threatening 
diseases [11], such as rheumatoid arthritis, type 2 diabetes mellitus, cardiovascular 
disease, and cancer [11]. Underpinning the risk association between obesity and these 
diseases is the accumulation of excess adipose tissue that elicits an aberrant innate 
immune response causing local and systemic chronic inflammation, the hallmarks of 
which include increased pro-inflammatory cytokine levels yielding increased production 
of free radicals, including ROS [13-15, 130]. 
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 The number of cancer cases worldwide attributable to obesity is substantial and 
increasing [23, 25, 132]. It is becoming more common for younger individuals to be 
diagnosed with obesity-related cancers [25], and women bear a greater burden than 
men [12, 25]. Contributing to this burden is the association between obesity and BCa, 
the most common cancer in women [26].  The association for obesity and diagnosis of 
ERα positive, hormone-dependent BCa in post-menopausal patients was recognized 
early [47]. A prevailing idea regarding the molecular mechanism is that ERα-positive 
cancer in post-menopausal women is fueled by estrogens that are synthesized by 
adipose tissue in response to inflammatory signaling factors [48]. More recent 
epidemiological studies report that obesity is a risk factor for TNBC diagnosis [4-10], 
and worse cancer-associated outcomes [28-32]. A TNBC diagnosis means that the 
tumor cancer cells lack expression of ER!, PR and the HER2 oncogene, a member of 
the epidermal growth factor family of receptor tyrosine kinases. Based on collective 
evidence that obesity-induced chronic inflammation is a common factor promoting other 
diseases, we reasoned that inflammation also serves as the general link between 
obesity and TNBC. However, the exact molecular mechanism remains unknown. 
 We previously identified that ROS-dependent expression of epigenetic reader 
MBD2, specifically the alternative mRNA splicing variant MBD2_v2, is crucial for 
maintenance and expansion of self-renewing CSCs in TNBC cell cultures [57]. 
Moreover, in heterogeneous cultures MBD2_v2 expression is contained in the CSC 
fraction [57]. The relevance of CSCs is that they are a subpopulation of cancer cells 
recognized as the source of malignant tumor initiation [73-75], and they give rise to drug 
resistance and metastatic recurrence [65, 76-78]. Due to its function to maintain and 
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promote expansion of tumor-initiating CSCs, ROS-dependent MBD2_v2 may be a key 
molecular feature driving TNBC incidence and recurrence. Considering that obesity is 
coupled with inflammation and ROS [130], we hypothesized that obesity can fuel an 
increase in MBD2_v2 expression to promote the tumor-initiating CSC phenotype in 
TNBC cells, setting a course to understanding why obesity is a risk factor for TNBC 
diagnosis and poor outcomes. Here, we report analysis of patient specimens and in vivo 
data supporting our hypothesis. Also, it was previously reported that SRSF2 is 
necessary for expression of MBD2_v2 in hPSCs [112]. We present new mechanistic 
evidence that ROS-dependent expression of SRSF2 drives TNBC MBD2_v2 expression 
and tumor-initiating CSCs. 
2.3 Results 
2.3.1 Associations between tumor MBD2_v2 expression and patient outcomes 
and BMI 
We hypothesized that obesity can cause an increase in MBD2_v2 expression to 
promote the tumor-initiating CSC phenotype in TNBC cells, setting a course to 
understanding why obesity is a risk factor for TNBC diagnosis and poor outcomes. To 
establish the plausibility of our hypothesis it was a priority to address the question: Do 
MBD2_v2 levels in TNBC patient tumor specimens associate with survival outcomes 
and BMI? Analysis using the KM Plotter database [133], testing for associations 
between gene transcript levels and relapse-free survival (RFS) among 246 specimens, 
showed that high expression of MBD2_v2 in TNBC patient tumors associates with high 
rates of relapse (Hazard ratio (HR)= 1.66, P = 0.05, Fig. 1A). The KM Plotter database 
lacks BMI data. To test for a relationship between patient BMI and tumor transcript 
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expression we used another existing probe-based gene expression dataset comprising 
59 TNBC specimens with known BMI status collected at KCI Detroit, MI (Table S1). 
Linear regression analysis indicated that there is a positive association for MBD2_v2 
expression and BMI (P = 0.04, correlation 0.27, Fig. 1B), and MBD2_v2 expression 
levels are significantly increased in tumors from patients with BMI ≥ 30 compared to 
tumors from patients with BMI < 30 (P = 0.03, Fig. 1C). Based on similar analysis of 
these data sets there is no association between tumor expression of the full-length 
isoform MBD2_v1 and patient BMI, and high MBD2_v1 expression is associated with 
low rates of relapse (Hazard ratio (HR)=0.68, P = 0.04, Fig. S2). The KCI dataset 
currently lacks a sufficient number of events to test for associations with outcomes. 
2.3.2 Increased tumor formation frequency and tumor MBD2_v2 expression in DIO 
mice 
 We investigated if obesity causes increased TNBC cell tumor initiation capacity 
and increased tumor MBD2_v2 expression using female B6.129S7-Rag1tm1Mom/J 
(B6.Rag1-/-) mice as a model for diet-induced obesity (DIO). Due to a homozygous 
Rag1 gene deletion this model lacks mature T and B lymphocytes [134]; therefore, it 
can be used for human tumor xenograft and cancer cell implant studies [135-137]. The 
B6.Rag1- / - model does, however, maintain macrophages with the capacity to 
recapitulate the pro-inflammatory environment and oxidative stress induced by 
increased adiposity [138]; and like its C57BL/6J background — the mouse strain most 
commonly used to study cancer and obesity [139] — B6.Rag1-/- presents a DIO 
phenotype that mimics human obesity [135, 137, 138, 140, 141]. We employed two 
TNBC cell lines, MDA-MB-231 and MDA-MB-468, and began by assessing the impact 
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of obesity on tumor formation rate. Groups of mice were randomly assigned either a 
control purified diet (kcal%=10, gram%=4.3); or a matched formula calorie-dense, high-
fat diet (kcal%=60, gram%=35). As was reported previously for female C57BL/6J and 
B6.Rag1-/- mice [137, 142], by day 35 the mice on the high-fat diet exhibited a 
significant weight increase relative to control mice (P < 0.001, Fig. 2A). On day 36, 
groups of DIO mice and lean controls were inoculated with MDA-MB-231 or MDA-MB-
468 cells. Mice were monitored for tumor formation up to 150 days post inoculation, and 
tumor formation frequencies were calculated. Relative to control mice, the tumor 
formation frequency for DIO mice was increased 2-fold for the MDA-MB-468 cell line 
(Fig. 2B), and approximately 4-fold for the MDA-MB-231 cell line (P = 0.025, Fig. 2C). 
The rates of MDA-MB-468 cell line tumor formation in each condition, control and DIO 
mice, were greater than the rates for MDA-MB-231 cells. MDA-MB-468 cultures, prior to 
inoculation, also expressed higher endogenous levels of MBD2_v2 relative to MDA-MB-
231 cells (Fig. S3). 
These experiments were devised to compare tumor formation rates, but tumor 
mass was plotted (Fig. 2D-E). The upward slopes of the growth curves are similar, 
indicating that DIO had little or no effect on the growth rates of established MDA-MB-
468 or MDA-MB-231 tumors. We performed semi-quantitative RT-PCR analysis of 
tumor MBD2_v2 expression. MBD2_v2 levels were higher in tumors harvested from 
DIO mice compared to tumors harvested from control mice (P < 0.001, Fig. 2F).  
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2.3.3 Increasing MBD2_v2 expression in TNBC cells increases tumor initiation 
capacity 
To more directly test if increased MBD2_v2 causes increased tumor initiation capacity 
we stably overexpressed MBD2_v2 in TNBC cells prior to inoculation. We proceeded to 
re-establish, as recently reported by us using other TNBC lines [57], that MBD2_v2 
overexpression promotes expansion of the CSC fraction in MDA-MB-231 TNBC cell 
cultures using a mammosphere formation assay. Stable overexpression of MBD2_v2 in 
cells by lentiviral transduction, confirmed by immunoblot and semi-quantitative RT-PCR 
analysis (Fig. 3A-B), caused a marked increase in the numbers of mammospheres that 
grew from equal seeding under non-attachment serum-free culture conditions relative to 
a stable green fluorescent protein (GFP) expressing MDA-MB-231 control cell line (Fig. 
3C). We inoculated mice with MBD2_v2 overexpressing or GFP-expressing MDA-MB-
231 cells. By day 100, 6 of 6 mice inoculated with MBD2_v2 overexpressing MDA-MB-
231 cells bore tumors, yet at the same time only 1 of 6 mice carried tumors in the GFP 
control group (Fig. 3D). The experiment was extended to 150 days post-inoculation; at 
which point 3 of 6 mice remained tumor-free in the GFP control group (Fig. 3D). Tumor 
mass was documented over the course of the experiment, and according to growth 
curve plots MBD2_v2 overexpression did not affect the rate of tumor growth (Fig. S4). 




2.3.4 TNBC cell MBD2_v2 expression depends on antioxidant-sensitive SRSF2 
expression 
It is reported that splicing factor SRSF2 is necessary for expression of alternative 
mRNA splicing variant MBD2_v2 in hPSCs [112]. We designed a set of experiments to 
examine if the same regulatory relationship between SRSF2 and MBD2_v2 exists in 
TNBC cells. First, we observed that expression of SRSF2 is, like MBD2_v2 [57], subject 
to antioxidant-sensitive, ROS-regulation in TNBC cells. Using MDA-MB-468 and 
SUM149 TNBC cell lines, which expressed similarly abundant endogenous levels of 
SRSF2, (–)-epicatechin antioxidant treatment reduced ROS and MBD2_v2 levels (Fig. 
S5), and downregulated SRSF2 mRNA and protein levels (Fig. 4A-B). We then 
established two independent SRSF2 stable KD (using two unique short-hairpin RNA 
(shRNA) sequences) and non-silencing vector control MDA-MB-468 cell lines. The KD 
of SRSF2 resulted in decreased MBD2_v2 protein and mRNA levels (Fig. 4C-D). 
According to mammosphere formation assays, SRSF2 KD also resulted in fewer 
mammospheres (Fig. 4E), and a reduction in size of those that did survive (Fig. 4F). 
Altogether, this characterizes a role for the ROS-dependent SRSF2–MBD2_v2 
regulatory axis in TNBC cells.  
2.3.5 Tumor SRSF2 expression is increased in DIO mice, and down-regulation of 
SRSF2 hinders tumor initiation capacity of TNBC cells 
We performed semi-quantitative RT-PCR analysis for SRSF2 expression in tumors 
harvested from DIO and control mice. Like MBD2_v2 (Fig. 2F), SRSF2 levels were 
consistently higher in tumors harvested from DIO mice (P < 0.001, Fig. 5A). To more 
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directly assess if increased SRSF2 has a role in increased tumor initiation capacity, we 
selected one of the stable KD cell lines (SRSF2 sh2) to test if down-regulating SRSF2 
yields decreased tumor initiation capacity in the high tumorigenic context of MDA-MB-
468 cells in DIO mice. SRSF2 KD cells demonstrated significantly delayed tumor 
initiation relative to non-silencing control cells (P < 0.05, Fig. 5B). By day 24 post 
inoculation, tumors were formed in 100% of mice inoculated with non-silencing control 
cells (6 of 6), and at the same time point only 33% of mice (2 of 6) bore tumors in the 
SRSF2 KD group (Fig 5B). Tumor mass was also documented over the course of the 
experiment, and there was no significant difference in growth rates comparing SRSF2 
KD and control tumors (Fig. S6). This remains consistent with insight that SRSF2–
MBD2_v2 promotes CSCs, which are not highly proliferative [78]. According to semi-
quantitative RT-PCR analysis SRSF2 KD was lost in established tumors (Fig. S6). In 
addition, high expression of SRSF2 in TNBC patient tumors associates with high rates 
of relapse (Hazard ratio (HR) = 1.57, P = 0.04, KM Plotter database, Fig. 5C). However, 
analysis of the KCI dataset, which revealed an association between MBD2_v2 and BMI 
(Fig. 1b and 1c), failed to identify an association between SRSF2 expression and BMI 
(Fig. S6). 
2.4 Discussion 
 TNBC is a molecular subtype that accounts for 15% of invasive BCa diagnoses 
[143, 144]. Incidence rates in developing countries and among women of African 
ancestry are higher [143, 144]. TNBC is also more prevalent in younger, pre-
menopausal women [38, 145], and obesity is a risk factor for TNBC diagnosis [4-10], 
and worse cancer-associated outcomes [28-32]. Ultimately, women diagnosed with 
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TNBC have the lowest 5-year survival rates among all BCa patients, in large part due to 
a lack of therapeutic options [146]. For TNBC the molecular drivers remain uncertain 
and targeted therapies do not exist. Moreover, development of transformative treatment 
strategies for TNBC must first identify and then find a way to target factors driving the 
tumor-initiating CSCs, which also give rise to drug resistance and metastatic recurrence 
[32, 76-78]. These clinical challenges further underscore the value of our investigation. 
Based on a review of the literature, we have generated the earliest reports on the 
role of epigenetic reader and alternative mRNA splicing variant MBD2_v2 to sustain and 
promote the tumor-initiating CSC phenotype; first based on studies conducted in 
vitro [57, 147], and now based on in vivo experiments that link it to obesity. The results 
herein also elucidate that splicing factor SRSF2 is necessary for expression of 
MBD2_v2 in TNBC cells and for CSC survival. Moreover, SRSF2 and MBD2_v2 
expression in TNBC cells is dependent on antioxidant-sensitive ROS. We investigated if 
obesity impacts SRSF2 and MBD2_v2 by inoculating a DIO mouse model with tumor-
forming TNBC cell lines, and in agreement with our hypothesis SRSF2 and MBD2_v2 
expression levels were significantly upregulated in tumors harvested from DIO mice 
displaying increased tumor formation rates. The DIO mice readily exhibited increased 
visceral adiposity and we verified that systemic oxidative stress levels were increased in 
DIO mice relative to control mice by measuring liver malondialdehyde, a lipid 
peroxidation marker [148] (Fig. S7); but a possible shortcoming of our study is that we 
did not attempt to treat DIO mice systemically with (–)-epicatechin antioxidant in order to 
affirm that inflammation, ROS specifically, was regulating increased SRSF2 and 
MBD2_v2 expression in TNBC cell line-derived tumors as in TNBC cell line cultures 
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(Fig.4A) [57]. However, it is well-documented in the literature that dysfunctional adipose 
tissue and resident macrophages function as an endocrine organ, producing pro-
inflammatory cytokines that directly act on tumors [17], and more detailed insights for 
how the B6.Rag1-/- DIO mouse model system likely parallels human physiology in this 
regard came to light when we applied genome-wide analysis to evaluate the greater 
impact of DIO on TNBC tumor gene expression. The significant results highlighted 
evidence of the effects of pro-inflammatory cytokines, specifically interferon gamma 
(IFNγ) signaling (Fig. S7). Circulating IFNγ is produced by adipocytes in obese 
individuals and IFNγ levels are elevated by DIO in B6.Rag1-/ - mice [149, 150]. 
Activation of BCa cell IFNγ receptors increases ROS levels, specifically hydrogen 
peroxide [151]. Also in obese BCa patients, increased macrophage infiltration of breast 
adipose tissue yields additional paracrine-acting pro-inflammatory cytokines [152].  
For experiments designed to more directly assess if increased expression of 
MBD2_v2 and SRSF2 play a causative role in increased tumor formation, we stably 
modified the levels of MBD2_v2 or SRSF2 in TNBC cells prior to inoculation. MBD2_v2 
overexpression significantly increased tumor initiation capacity of TNBC cells in lean 
mice; and SRSF2 KD, which decreased MBD2_v2 expression, significantly hindered 
tumor formation capacity in the more tumorigenic context of DIO mice. The relevance of 
the experimental methodology to inoculate mice with cancer cells to measure efficiency 
of tumor formation, or tumorigenicity, was previously established [90]. Researchers 
observed that relatively small numbers of cells exhibiting the CSC phenotype possess 
the capacity to macro-colonize and subsequently form tumors in mice; but greater 
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numbers of cells with alternate phenotypes, referred to as bulk cancer cells, fail to 
macro-colonize [90]. 
The in vitro and in vivo experimental data presented here support that the 
SRSF2–MBD2_v2 regulatory axis is a feature necessary for maintenance of TNBC 
tumor-initiating CSCs that can be induced to expand the CSC fraction (Fig. 6). 
Therefore, SRSF2–MBD2_v2 expression would not be exclusive to, but increased in 
TNBC tumors from obese patients and patients with poor survival outcomes. Results 
from our analysis of patient tumor sample data are in-line with this idea. KM plotter 
database inquiries revealed that high mRNA expression of MBD2_v2 and SRSF2 in 
TNBC specimens associates with high rates of relapse. MBD2_v2 levels also positively 
associate with BMI and are significantly higher in tumors from obese women; however, 
the same dataset did not show an association for SRSF2 and BMI. This does not 
necessarily contradict our mechanistic evidence that MBD2_v2 expression in TNBC 
cells depends on SRSF2; it may reflect that differences in SRSF2 mRNA levels are 
small and challenging to discern in analysis of RNA from patient formalin-fixed paraffin-
embedded (FFPE) cancer specimens. This rationale is in-line with results from our 
analysis of tumors harvested from DIO mice relative to lean controls: SRSF2 expression 
was increased 4-fold in DIO tumors and its target, MBD2_v2 expression, was increased 
20-fold. 
The function of MBD2_v2 to regulate TNBC CSCs is underscored by the 
necessity for MBD2_v2 to maintain the self-renewing capacity of hPSCs [112]. A report 
by Lu et al. details the mechanism whereby MBD2_v2 activates essential hPSC factors 
such as NANOG [112]. We also observed that increasing MBD2_v2 upregulates stem 
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cell marker NANOG expression in TNBC cells, and NANOG levels are increased in 
tumors harvested from DIO mice relative to tumors from control mice (Fig. S8). NANOG 
expression is detected in normal mammary stem cells, and decreases upon 
differentiation. Furthermore, NANOG expression is associated with high-grade TNBC 
and worse patient outcomes	[153]. The strong association between NANOG expression, 
high-grade TNBC and worse outcomes is likely directly related to its CSC-specific 
expression [78], and CSC enrichment is associated with obesity [49-57]. Our data 
reinforce that obesity promotes CSCs, through activation MBD2_v2, which similar to 
embryonic stem cells (ESCs), regulates pluripotency transcription factor expression to 
drive self-renewal capacity.  
Moving forward, we will continue work to elucidate the mechanistic pathway 
leading to aberrant, upregulated MBD2_v2 expression dependent on ROS and likely 
subject to inflammation related to obesity. Another priority is to study if SRSF2 and 
MBD2_v2 play a role in malignant transformation of partly transformed or noncancerous 
breast epithelial cells, and if this too may be induced by obesity. It is notable that the 
dataset used to uncover the positive association between MBD2_v2 expression and 
BMI consists entirely of specimens from African American women. African American 
women are approximately 2 times more often obese relative to EA women [154]  and a 
TNBC driver mechanism fueled by obesity could contribute to the worse TNBC 
outcomes and higher incidence of TNBC among African American women [124, 143]. 
We expect the association between MBD2_v2 and BMI to be similar irrespective of 
race, yet it is possible that planned analysis of tumors from EA women will not so readily 
demonstrate the association. Conversely, lifestyle factors contributing to systemic 
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inflammation independent of obesity such as sleep deprivation and psychosocial stress 
are also more prominent in African Americans [155-158]; and inflammation in non-
obese patients may influence the SRSF2-MBD2_v2 axis and be a confounding variable 
for the association between obesity and MBD2_v2 expression in tumors from African 
American women. Either way, our study provides a new avenue for research to 
understand the molecular biology of race-associated TNBC disparities.   
Finally, in our retrospective analysis of MBD2_v2 expression in patient tumor 
data we used the threshold BMI ≥ 30kg/m2 to define obesity [11]. Obesity is a medical 
condition that applies to overweight individuals with excess visceral adiposity [11]. While 
it is applicable to estimate obesity in the general population, a BMI calculation does not 
measure adipose tissue, nor does it inform an individual of their body fat distribution. 
Calculating the waist-to-hip ratio or more directly measuring body fat percentage are 
likely to provide more accurate assessments of patient adiposity, and results from 
research employing alternate approaches are raising awareness that the use of BMI 
and the BMI ≥ 30kg/m2 threshold to define obesity is underestimating rates of obesity 
and the impact of obesity on patients [159, 160].  However, these types of data are not 
standard clinical information and were not available for our analysis. Moreover, the data 
used to calculate BMI (weight and height) are routinely available and the threshold BMI 
≥ 30kg/m2 proved useful to establish that obesity is an adverse risk factor for TNBC [4, 
5, 7-10].  
2.5 Conclusions 
 The current report describes evidence to support that MBD2_v2 expression is 
responsive to obesity and drives TNBC tumorigenicity, and thus provides molecular 
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insights in support of the epidemiological evidence that obesity is a risk factor for TNBC. 
The majority of TNBC patients are obese [161, 162] and rising obesity rates threaten to 
further increase the burden of obesity-linked cancers [132], which reinforces the 
relevance of this area of study. 
These data also contribute to our understanding of CSC biology, and the function 
of MBD2_v2 in driving tumor-initiating CSC self-renewal. More specifically, these data 
provide evidence supporting that obesity could be driving the TNBC CSC subpopulation 
via upregulation of MBD2_v2-mediated expression of transcription factors that regulate 
pluripotency, such as NANOG, through aberrant activation of an evolutionarily 
conserved epigenetic regulatory pathway. The mechanisms, by which MBD2_v2 is 
directed to specific genomic regions, and directly or indirectly functions in positively 






Figure 1. Associations between expression of MBD2_v2 in TNBC patient tumor specimens and 
survival outcomes and BMI. (A) Analysis was performed with the online KM Plotter database, using a 
logrank test of association between relapse-free survival and MBD2_v2 transcript level. The number of 
subjects at risk at different time points is indicated below the x-axis. Testing for gene transcript level 
associations with BMI, was done using a separate gene expression microarray dataset generated from 
TNBC specimens collected at the Karmanos Cancer Institute, Detroit, MI, where BMI data 
corresponding to deidentified samples was available. (B) The association between BMI and MBD2_v2 
expression was tested using linear regression analysis (P = 0.04, correlation 0.27). (C) The mean 
MBD2_v2 expression for tumors from obese patients with BMI ≥  30 was compared to the mean 
MBD2_v2 expression for tumors from non-obese patients with BMI < 30. Line is equal to the median 
value (BMI < 30 median = 2.7, BMI ≥ 30 median = 3.5). The P value was calculated using a Student’s t-
test (one-sided). The number of patients (n) per group is indicated.
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Figure 2. Tumor formation frequency and tumor MBD2_v2 expression are increased in DIO mice. 
(A) The mean body weight over time for DIO mice on the high-fat, calorie-dense formula diet and mice on 
control formula diet. On day 35 the weight increase in DIO mice was 10%, P < 0.001. (B) MDA-MB-468 or 
(C) MDA-MB-231 TNBC cells were used to inoculate control and DIO female mice by subcutaneous flank 
injection. From time of inoculation, tumor formation frequency and time to initiation were measured over 
150 days. The P values were calculated using Gray’s test. P values ≤ 0.05 are reported. (D) MDA-MB-468 
and (E) MDA-MB-231 tumor mass was plotted for all tumors formed with modeled growth (bold) 
superimposed. A generalized least squares test was used to calculate P values (P > 0.05). (F) 
Semiquantitative RT-PCR analysis was performed to measure MBD2_v2 transcript levels in RNA harvested 
from MDA-MB-468 tumors, comparing tumors harvested from DIO mice (n = 3 randomly selected) to those 
from control mice (n = 3). Data are expressed as the relative means ± s.e.m., Welch’s t-test was used to 




Figure 3. MBD2_v2 overexpression in TNBC cells increases in vivo tumor initiation 
capacity. (A) Stable overexpression of MBD2_v2 isoform in the MDA-MB-231 cell line was 
confirmed by semiquantitative RT-PCR analysis (relative means ± s.d. of three technical 
replicates); (B) and by immunoblot analysis of nuclear lysates, with nucleoporin p62 serving as the 
loading control. (C) MBD2_v2 overexpressing MDA-MB-231 cells or GFP-expressing control 
MDA-MB-231 cells were seeded equally under serum-free non-adherent conditions in a 
mammosphere formation assay. Images documenting the differences in numbers of spheres 
formed were taken after 7 days. Bar = 50 µm, 4x magnification. (D) MBD2_v2 overexpressing or 
GFP-expressing MDA-MB-231 cells were subcutaneously inoculated by injection into the flank 
regions of mice, n = 6 per group. At day 100, the difference in tumor formation frequency was 
calculated (P = 0.02, Fisher’s exact test). At 150 days post inoculation, the difference in 





Figure 4. Knockdown of SRSF2 decreases MBD2_v2 levels in TNBC cells. (A) The effect of 
(–)-epicatechin (Epi) antioxidant treatment (48 hours, 120 µM) to reduce readily detectable SRSF2 
levels in MDA-MB-468 and SUM149 TNBC cell lines was measured by semiquantitative RT-PCR 
analysis of RNA, (B) and by immunoblot analysis of protein lysates. Semiquantitative RT-PCR 
(mean fold-change for sets of 3 technical replicates ± s.d.) and immunoblot data are 
representative of 2 independent experiments for each cell line. (C) Confirmation of stable 
knockdown of SRSF2 in MDA-MB-468 cells, and the impact of SRSF2 knockdown on MBD2_v2 
levels, was measured by semiquantitative RT-PCR analysis (relative means of 3 technical 
replicates ± s.d.); (D) and by immunoblot analysis. (E) A mammosphere formation assay was 
used to simultaneously observe the impact of SRSF2 knockdown by each shRNA construct on 
the numbers of mammospheres, (F) and the size of mammospheres formed. Images and counts 
were taken 7 days after passaging to serum-free, non-adherent conditions. Results in E and F are 
one complete set of data and are representative of 2 independent experiments. Bar = 500 µm, 4x 





Figure 5. Tumor SRSF2 expression is increased in DIO mice, and downregulation of SRSF2 
hinders tumor formation. (A) Comparison of SRSF2 levels in wild-type MDA-MB-468 tumors 
harvested from DIO mice (n = 3 randomly selected) and lean control mice (n = 3). Relative means  
SEM, P value Welch’s t-test. (B) SRSF2 knockdown and nonsilencing vector control MDA-MB-468 
cells were subcutaneously inoculated by injection into the flank regions of mice, n = 6 per group. 
Gray’s test of difference in cumulative incidence was used to calculate the P value. (C) Analysis 
was performed with the online KM Plotter database, using a logrank test of associations between 
relapse-free survival and SRSF2 transcript levels. The number of subjects at risk at different time 




Figure 6. Summary and Conclusions. The mechanism underlying increased 
TNBC risk associated with obesity remains unknown. Results of studying TNBC 
cells in a diet-induced obesity mouse model and patient tumor data indicate 
regulation of tumor-initiating cancer stem cells by mRNA variant MBD2_v2 is key. 
Moreover, MBD2_v2 levels in TNBC cells, governed by ROS and splicing factor 
SRSF2, increase under conditions of obesity.
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CHAPTER 3: MBD2_V2 PROMOTES SELF-RENEWAL CAPACITY OF PROSTATE 
CANCER CSCS 
The data presented in this chapter were published on June 12th, 2018 in the journal 
Molecular Oncology	[147].  
3.1 Preface 
 RNA-sequencing of human tissue samples was performed in collaboration with 
the KCI Genomics core, the Translational Genomics Research Institute (TGen), the 
Wayne State University Department of Pathology and the KCI Biostatistics core 
facility. Bioinformatic processing and quality control assessment were performed in 
collaboration with Dr. Christophe Legendre at TGen. Statistical analyses were 
performed in collaboration with Dr. Gregory Dyson at KCI. 
 3.2 Introduction 
 There are approximately 160,000 new cases of PCa and 26,730 PCa-related 
deaths annually in the United States	 [125], making PCa the second leading cause of 
cancer-related deaths for American men. Recent statistics also reveal that race 
disparities persist despite improvements in PCa detection, access to care, and survival 
across all demographics	 [117, 125, 126]. AAM have a 70% higher incidence rate and a 
two-fold to five-fold greater risk of dying from the disease compared to EAM [117]. 
Moreover, AAM diagnosed with low-risk prostate cancer are more likely to harbor higher 
risk disease [127]. The cause of these disparities is likely multifaceted, including 
undetermined contributions from ancestry genetics and lifestyle risk factors [120-124], 
(and reviewed in Powell and Bollig-Fischer (2013)). This raises the fundamental 
motivation for our work: that the molecular underpinnings for race disparities in PCa, 
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which remain to be understood, may one day be exploited to advance clinical decision-
making and improve outcomes for all patients.  
 Traditionally, AAM have been poorly represented in reports of molecular genomic 
aberrations in PCa. Recent research has begun to address this shortcoming and to 
highlight the greater molecular complexity of the disease. Most notably, it is validated 
that the tumor protein p53 (TP53) somatic aberrations and TMPRSS2-ERG fusions 
occur significantly less often in tumors from AAM relative to EAM [163-167]. 
Amplification of the fatty acid synthase 
(FASN) gene, however, was found to be more frequent in PCa samples from AAM 
[163], and this is consistent with our finding that FASN mRNA expression is increased in 
PCa from AAM relative to EAM [128]. 
 In the current study, we performed RNA-sequencing analysis to further 
understand the molecular diversity of PCa by specifically investigating high-grade PCa 
[Gleason Score (GS) ≥ 7(4 + 3)] in relation to matched non-cancer adjacent tissue 
across AAM and EAM. Here, our RNA-sequencing data analysis identified cytokine 
signaling factors including IL-6 as showing race-specific differential expression. For 
AAM, IL-6 was upregulated in the nonmalignant adjacent tissue, but for EAM, IL-6 
expression was higher in PCa tissue.  
 Much effort has been put forth to study the mechanistic role of IL-6 in PCa, 
supporting that IL-6 is a key cancer-promoting factor and rational therapeutic target 
[168-170]. However, this narrative is challenged by reports such as one from Pencik et 
al. (2015) showing that signal transducer and activator of transcription 3 (STAT3) 
activation, the downstream effector of IL-6 signaling, suppresses PCa progression 
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[171]. Moreover, clinical trials using antibodies to target IL-6 failed to provide benefit to 
PCa patients [172, 173]. Yet, increased levels of IL-6 in patient serum associated with 
poor outcomes [174], and serum IL-6 levels are known to be higher in AAM than in EAM  
[175]. The importance of IL-6 in PCa race disparities remains unresolved. 
In the US, AA patients have higher serum IL-6 levels, associated with higher 
rates of obesity [46, 176, 177]. Moreover, obesity is associated with  increased PCa risk 
[113-116], and IL-6 signaling in PCa CSCs is linked with increased ROS, a hallmark of 
obesity [169]. In Chapter 2, we demonstrated that obesity promoted tumor initiating 
TNBC CSCs, via MBD2_v2 upregulation [57, 103]. We hypothesized that MBD2_v2 
mediated regulation of CSCs could be similarly occurring, to drive PCa CSCs, as TNBC 
also disproportionately impacts AAM, and both diseases are associated with obesity-
related risk.   
The RNA-sequencing results that we report herein associated with AAM also led 
us to recognize the potential for microenvironment-derived (exogenous) IL-6 to 
inactivate tumor suppressor TP53 in PCa cells. The importance of TP53 downregulation 
is in addition to the fact that TP53 somatic aberrations occur significantly less often in 
tumors from AAM relative to EAM [163-167]. However, previous reports show that loss 
of WT TP53 is required for CSC viability [178, 179], and that TP53 deletion and low p53 
immunohistochemical positivity staining are both associated with worse PCa outcomes 
[180]. As stated above AA PCa tumors harbor fewer TP53 mutations, suggesting that 
TP53 inactivation could be epigenetically regulated.  
Using a panel of PCa cells, including cell lines from AAM, we demonstrate that 
exogenous IL-6 upregulates expression of MBD2_v2 to promote CSCs, and also 
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downregulates WT TP53 expression in IL-6 non-expressing PCa cell lines. The work we 
describe here advances what is known about the biology associated with PCa race 
disparities and molecular signaling promoting CSCs. 
3.3 Results 
3.3.1 RNA-sequencing analysis of PCa and non-cancer prostate tissue from AAM 
and EAM 
 We analyzed RNA-sequencing normalized read count differences between tumor 
and adjacent nonmalignant tissue samples as a function of race. Plots for the nine most 
significant differentially expressed genes among the resulting 1206 significant coding 
genes identified are provided in Fig. S3. We then applied the Enrichr tool [181] to the 
significant gene set to identify significant signaling pathways overrepresented in the 
data. Cytokine–cytokine receptor interaction was the most significant pathway (Fig. 1A). 
The genes associated with this pathway in our dataset are provided in Table S2. Among 
them, IL-6 and TGFB1 were upregulated in the non-cancer, tumor-adjacent tissue of 
AAM, but for EAM, IL-6 expression was increased in PCa tissue and TGFB1 was not 
differentially expressed (Fig. 1B). We further examined our significant gene set using 
the Upstream Regulator tool	[182]. Upstream Regulator analysis compared our input list 
of differentially expressed genes to a catalogue of perturbed datasets to consider the 
significance of gene overlap and direction of expression differences to predict the 
activity of upstream regulators. This revealed a significant overrepresentation and 
coordinated change in mRNA expression in AAM tumor data for genes that are known 
to be regulated by tumor suppressor protein TP53 (Fig. 1C). Specifically, the direction of 
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differential expression of genes downstream of TP53 suggested that TP53 inactivation 
was occurring in PCa from AAM (Fig. 1D). 
3.3.2 IL-6 treatment promotes CSC growth in IL-6 non-expressing PCa cell 
cultures 
 Our RNA-sequencing analysis of high-grade PCa and non-cancer adjacent 
tissues revealed differential IL-6 expression specific to race (Fig. 1). The data from AAM 
suggest a paracrine role for IL-6, but IL-6 expression was enriched in PCa specimens 
from EAM, indicating that for some high-grade tumors, PCa cells may express 
autocrine-acting IL-6. We set out to further distinguish the role of IL-6 using a diverse 
panel of PCa cells, including cell lines from AAM. 
We began by characterizing IL-6 expression levels in our cell line panel. Based 
on results of real-time RT–PCR analysis using TaqMan probes, IL-6 mRNA was not 
detected in MDA-PCa-2b, RC77T or LNCaP cells, but was highly expressed in PC3 and 
DU145 cells (Table 1). The results in Table 1 are annotated with the information that 
MDA-PCa-2b and RC77T were derived from PCa from AAM. Also, the cell lines 
expressing IL-6 are TP53 mutant. IL-6 mRNA was not detected in TP53 WT cell lines 
(Table 1).  
It was previously reported that IL-6 signaling in PCa sustains and promotes the 
generation of CSCs [169, 183]. We proceeded to measure the impact that IL-6 had on 
promoting CSCs across our PCa cell line panel. Using a prostasphere formation assay, 
we tested whether IL-6 treatment influenced the formation of prostaspheres, 
demonstrating the presence of CSCs [86]. In the AA-derived MDA-PCa-2b cells, which 
do not express IL-6, we observed an increase in the number of prostaspheres after 7 
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days of low-dose IL-6 treatment, with a higher IL-6 concentration eliciting a more 
significant increase in the number of prostaspheres (Fig. 2A). We further observed that 
within 48 h, MDA-PCa-2b cell viability also increased in a dose-dependent manner (Fig. 
2B). We then tested IL-6 treatment on cultures of RC77T cells, which are also of AA 
origin and TP53 WT, and do not express IL-6. Similar to MDAPCa-2b cells, IL-6 
treatment induced greater numbers of prostaspheres (Fig. 2C) and increased cell 
viability similar to MDA-PCa-2b cells (Fig. 2D). For PC3 cells, which are TP53 mutant 
and express high levels of IL-6 endogenously, IL-6 treatment had no effect on 
prostasphere growth (Fig. 2E). However, treatment of PC3 cells with the IL-6 receptor 
inhibitor tocilizumab reduced prostasphere formation (Fig. 2F).  
The impact of IL-6 on CSCs on other prostate cancer cell lines in our panel was 
measured by fluorescence‐activated cell sorting (FACS), where the fraction of CSCs 
was measured based on triple-marker-positive status (CD44+/CD133+/EpCAM+). This 
assay distinguishes prominin 1 (CD133)-positive CSCs relative to non-CSCs, also 
referred to as bulk cancer cells, which do not express CD133. CD133 is a specific PCa 
CSC surface marker [91]. For IL-6 expressing DU145 cell line cultures, IL-6 treatment 
for 7 days had no effect on the fraction of triple-marker-positive cell numbers. However, 
for IL-6 non-expressing LNCaP cells, a similar 7-day IL-6 treatment regimen induced a 
threefold increase in the percentage of triple- marker-positive CSCs (Fig. 2G, Table S3). 
Results using PC3 again showed that IL-6 treatment had no effect on prostaspheres 
(Fig. 2G). For IL-6 non-expressing RC77T cells, an increase in the percentage of triple-
marker-positive CSCs was significant at 14 days of treatment (Fig. 2G, Table S3). 
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3.3.3 IL-6 treatment induced expression of alternative mRNA splicing variant 
MBD2_v2, which promotes CSCs 
We recently identified in TNBC, an aggressive BCa subtype that 
disproportionately affects AA women [143], that expression of the epigenetic reader 
protein and mRNA splicing variant MBD2_v2, is dependent on ROS and necessary to 
maintain the CSC phenotype [57]. In generating PCa CSCs, IL-6 activity is coupled with 
the production of ROS, which functions as second messenger signaling factor [169]. 
Therefore, we hypothesized that IL-6 treatment of PCa cells upregulates expression of 
MBD2_v2 and that increased MBD2_v2 expression promotes PCa CSCs. We tested 
this using IL-6 non-expressing RC77T and LNCaP cells. As can be seen from 
immunoblot analysis, IL-6 treatment induced increased protein and mRNA expression of 
the MBD2_v2 isoform in both cells lines (Fig. 3A,B). Levels of the long isoform, mRNA 
variant MBD2_v1, were not affected by IL-6 treatment (Fig 3A). The addition of a 
pharmacological STAT3 inhibitor blocked IL-6 induction of MBD2_v2 (Fig. 3C), 
corroborating the role of exogenous IL-6 signaling via STAT3. Treatment with a STAT3 
inhibitor alone downregulated MBD2_v2 (Fig. 3D), and prostaspheres (Fig. 3E) in IL-6 
expressing DU145 cells, indicating that MBD2_v2 levels and prostaspheres were 
sustained by the endogenous IL-6 signaling in this cell line. Regarding STAT3 
immunoblotting, each of the panels (Fig. 3A,C,D) demonstrate that STAT3 phospho-
protein levels (pSTAT3) were induced by IL-6 treatment, while total protein levels were 
unaffected, which is consistent with canonical IL-6 signaling. 
 We proceeded to stably overexpress MBD2_v2 in LNCaP cells to assess the 
impact on CSCs via a prostasphere formation assay. Under nonattachment, serum-free 
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conditions overexpression of MBD2_v2 led to a significant increase in prostasphere 
numbers and an increase in prostasphere size relative to GFP expressing controls (Fig. 
4A–C, Fig. S4). We subsequently performed the same experiment using the AA patient-
derived RC77T prostate cancer cell line, and the results were essentially the same (Fig. 
4D–F, Fig. S4), underscoring that although a molecular phenotype may be enriched in 
PCa from AAM (i.e., TP53 wild-type (WT), IL-6 derived from the environment), it is not 
exclusive to PCa from AAM. A report by Lu et al. (2014) details the mechanism whereby 
in hPSCs, MBD2_v2 activates genes such as NANOG and SOX2. It is well known that 
SOX2 and NANOG directly interact and regulate self-renewal of hPSCs and CSCs [184-
186]. We proceeded to test whether MBD2_v2 regulates the mRNA expression of SOX2 
and NANOG in the context of PCa cells. SRY-box 9 (SOX9) was also of interest to us 
based on a recent report that it fulfills a molecular function similar to SOX2, but may 
have a predominant role in therapy resistant PCa [187]. The results complete a set of 
experiments providing evidence that exogenous IL-6 treatment upregulates MBD2_v2 in 
TP53 WT LNCaP and RC77T cells (Fig. 3) and that upregulated MBD2_v2 by stable 
overexpression in RC77T cancer cells upregulates NANOG, SOX2, and SOX9 (Fig. 
4G–I). In LNCaP cells, only NANOG increased with MBD2_v2 overexpression (Fig. 4G). 
Perhaps giving some indication of differences for these two cell lines that had up to now 
in the course of our study appeared molecularly similar. Although based on the literature 
the cell function outcome will be the same: increasing any single one of these factors 
will likely promote the stemmness phenotype [184-187] 
Finally, analysis of Affymetrix microarray expression data sets, accessed via 
Oncomine [188], demonstrated that GS 8-9 PCa express significantly higher levels of 
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MBD2_v2 relative to GS 4-7 PCa (Fig. 4J). Conversely, further analysis showed an 
inverse relationship between variant MBD2_v1 expression and PCa GS (Fig. 4K).  
3.3.4 IL-6 treatment decreased WT TP53 protein in IL-6 non-expressing cells 
 As described above, results of our RNA-sequencing data analysis pipeline 
revealed that IL-6 was at significantly higher levels in the non-cancer, tumor-adjacent 
tissue of AAM relative to PCa from AAM and tumor-adjacent tissue from EAM. Also, 
although TP53 itself was not differentially expressed, the significant results from 
Upstream Regulator Analysis identified evidence for inactivation of WT TP53 signaling 
in PCa from AAM (Fig. 1C,D). We predicted that these findings were related and 
hypothesized that microenvironment-derived IL-6, or exogenous IL-6 treatment in 
culture, downregulates WT TP53 protein levels in PCa cells. WT TP53 function is 
known to play a role in inhibiting the CSC phenotype [178, 179], thus, this hypothesis is 
also relevant to IL-6 promotion of CSCs. To test it, we measured the effect of IL-6 
treatment on TP53 levels using IL-6 non-expressing, TP53 WT cell lines RC77T and 
LNCaP. Immunoblot analysis demonstrated that TP53 protein levels decreased in both 
RC77T and LNCaP cells treated with IL-6 (Fig. 5A). Real-time RT–PCR analysis 
validated that IL-6 treatment did not induce TP53 mRNA level changes (data not 
shown). Also, for IL-6 expressing DU145 cells, IL-6 treatment had no effect on mutant 
TP53 levels (Fig. 5A). Lastly, by real-time RT–PCR analysis we tested the effect of IL-6 
treatment on the expression of genes that are known to be regulated by WT TP53 
function using the RC77T cell line. We selected to test EPH receptor A2 (EPHA2) and 
versican (VCAN) because they are among the significant results from the RNA-
sequencing data analysis results associated with specimens from AAM in Fig. 1D, and 
43 
	
because they are regulated by direct TP53-DNA binding [189]. We also tested the more 
commonly studied TP53-regulated factor cyclin-dependent kinase inhibitor 1A 
(CDKN1A), otherwise known as p21. For all three genes, mRNA expression levels 
decreased with IL-6 treatment (Fig. 5B). 
3.4 Discussion 
 We began this investigation with RNA sequencing of PCa patient specimens, 
which produced new evidence of molecular diversity for high-grade PCa associated with 
race. Our analysis identified race-specific differential gene expression comparing tumor 
and non-cancer adjacent tissue samples. Countering a previous report that PCa tumors 
lack IL-6 expression [190], our RNA-sequencing data analysis highlighted that PCa 
tumors from EAM, and by extension PCa cells, express relatively high levels of IL-6. We 
measured IL-6 expression across a diverse PCa cell line panel. DU145 and PC3 PCa 
cell lines expressed abundant IL-6 mRNA, but IL-6 was not detected in RNA harvested 
from LNCaP cells. Okamoto et al. (1997) reported similar findings based on 
measurement of IL-6 protein secreted from these cell lines [191]. Our panel also 
included RC77T and MDAPCa-2b derived from AAM, and with this expanded panel, we 
observed that IL-6 non-expressing PCa cell lines – LNCaP, RC77T, and MDA-PCa-2b – 
are TP53 WT. In contrast, IL-6 expressing cell lines – DU145 and PC3 – are TP53 
mutant. TP53 status in our diverse PCa cell line panel may reflect that TP53 mutations 
are less frequent in PCa from AAM relative to PCa from EAM [163, 165]. 
 The RNA-sequencing data analysis results associated with AAM led us to test 
the potential for microenvironment-derived, or exogenous IL-6 to downregulate WT 
TP53 protein in IL-6 non-expressing PCa cell lines. Immunoblot analysis showed that 
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IL-6 treatment caused a marked decrease in TP53 protein levels in TP53 WT cell lines. 
In parallel, we observed that IL-6 treatment had no effect on TP53 mRNA. Additional 
studies are needed to uncover the mechanism by which, WT TP53 protein is 
downregulated by IL-6 signaling in PCa cells. The requirement for TP53 downregulation 
in PCa CSCs is underscored by its known role in promoting differentiation of ESCs, and 
studies which show inactivation of TP53, supports reprogramming of somatic cells to 
induced hPSCs	 [192]. However, it is already reported that loss of WT TP53 is required 
for cancer cell expression of the stem cell phenotype [178, 179]. Moreover, low TP53 
WT protein levels in PCa are associated with worse outcomes [180], but it remains 
unclear whether higher IL-6 levels in the adjacent stroma and serum of AAM correlate 
with low levels of WT TP53 protein in PCa specimens from AAM.  
 We characterized the effect of IL-6 on CSCs in our PCa cell line panel. 
Summarizing the results of these experiments, IL-6 treatment of IL-6 non-expressing 
PCa cells elicited a significant, dose-dependent increase in the number of CSCs. For IL-
6- expressing PCa cell lines, adding IL-6 to the media of IL-6-expressing cells did not 
increase the number of CSCs. These data suggest that in IL-6-expressing PCa cell line 
cultures the IL-6 receptor population was saturated by endogenous IL-6 levels. Our 
work underscores that previous, unsuccessful clinical trials appropriately assessed the 
significance of IL-6 signaling in PCa progression, but may have failed in their approach 
to target IL-6 or IL-6 signal transduction factors JAK/STAT [172, 173, 193, 194]. Zhong 
et al. (2016) propose that a higher affinity IL-6 antibody with an extended half-life will 
contribute to solving the issue [170]. On the other hand, more thorough understanding 
of downstream IL-6 signaling mechanisms driving PCa CSCs could provide insights for 
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improved PCa treatment strategies. Our finding that IL-6 signaling upregulates 
expression of MBD2_v2, to support and promote expansion of the CSC niche in PCa, 
opens a novel avenue for research. CSCs are identified in patient tumors and tumor-
derived cell line cultures as a subfraction of self-renewing, tumor-initiating PCa cells that 
also give rise to drug resistance and metastatic recurrence	 [79]. The insight for us to 
test the effect of exogenous IL-6 treatment on MBD2_v2 expression, and subsequently 
observe that upregulated MBD2_v2 increases PCa CSCs, is based on results of our 
investigation into how ROS signaling promotes malignant transformation and the stem 
cell phenotype in TNBC cells [57]. Our current study identified that MBD2_v2 sustains 
PCa CSCs. Furthermore, a pro-inflammatory signaling environment (i.e., exogenous IL-
6) induces MBD2_v2 expression that drives expansion of the CSC population in TP53 
WT PCa cells, in a STAT3-dependent manner. With these two studies, we have 
uncovered a mechanism implicated in two cancer types that disproportionately impact 
African Americans. 
 We intend to pursue studies to uncover further mechanistic insights surrounding 
how MBD2_v2 expression is regulated by IL-6 in PCa. However, we can hypothesize 
that the mechanism by which MBD2_v2 functions to maintain and promote the 
generation of CSCs is similar to the mechanism described for hPSCs. MBD2_v2 is one 
of two alternative mRNA splicing variants for the epigenetic reader MBD2 gene and in 
hPSCs MBD2_v1 binds methylated CpG promoter sequence and recruits the NURD 
corepressor complex to silence transcription of pluripotency genes and promote cellular 
differentiation [112]. MBD2_v2 binds the same promoter sequences, but lacks the 
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domain required to recruit the NuRD complex; and upregulated MBD2_v2 displaces 
MBD2_v1 to promote stem cell phenotypes [112]. 
 Analysis using the Oncomine gene expression microarray database [188] 
showed that high MBD2_v2 expression in patient tumors correlated with high-grade 
PCa and that high MBD2_v1 expression correlated with low-grade PCa. We do not yet 
have preliminary insight as to whether MBD2_v2 is differentially expressed in PCa from 
AAM relative to EAM. Public gene expression data sets are lacking in AAM specimens, 
and despite having achieved approximately 100 million high-quality paired end reads 
per sample, MBD2_v2 mapped read counts were below the detection threshold in our 
RNA-sequencing data. This underscores the challenge of using genomewide RNA 
sequencing to analyze specific mRNA splicing variants [195].  
 Based on data from previous studies with a focus on PCa tissue, there appears 
to be no association between IL-6 levels in cancer cells and high-grade PCa [128, 171]. 
Herein, we report that AAM with high-grade cancer have significantly higher IL-6 
expression in the tumor microenvironment. Furthermore, AAM have higher circulating 
levels of IL-6 relative to EAM [127], and AAM are more likely to advance to higher grade 
disease [127]. Thus, further research to define the signaling mechanism for induction of 
MBD2_v2 expression in PCa, by IL-6 derived from the microenvironment, may be 
particularly relevant for AAM. 
3.5 Conclusions 
In conclusion, the results of the current study contribute to characterizing gene 
expression patterns in high-grade PCa and non-cancer tissues from EAM and AAM. 
The results advance molecular understanding of how IL-6 signaling promotes the CSC 
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phenotype in PCa cells derived from EAM and AAM (Fig 6.). Continued research is 
warranted to realize how these new insights for CSC biology can be exploited to 





















Figure 1. Analysis of RNA-sequencing data from PCa and matched noncancer adjacent tissue 
identified race-specific differential gene expression. RNA sequencing and interaction effect 
analysis were run on PCa and matched noncancer adjacent tissues from eight AAM and eight EAM 
(32 samples total, repeated). (A) The Enrichr tool was applied to the resulting significant gene set to 
identify KEGG signaling pathways overrepresented in the data. (B) Race-specific, differential gene 
expression patterns are shown for TGFB1 and IL-6, which were among the genes contributing to 
significant overrepresentation of the cytokine–cytokine receptor interaction pathway in (A). The 
interaction effect analysis P-value is provided. (C) Upstream Regulator analysis compared our input 
list of differentially expressed genes to a catalogue of perturbed datasets to consider the significance 
of gene overlap and direction of expression differences to predict the activity of upstream regulators, 
for example, transcription factors. The algorithm accounts for the direction of differential expression of 
genes downstream of an upstream regulator to calculate a negative activation z-score (predictive of 
inactivation) or a positive activation z-score (predictive of activation). (D) Enriched network of genes 
associated with TP53 function identified by Upstream Regulator Analysis. The patterns of expression 
displayed here represent PCa relative to noncancer adjacent tissues specific to AAM. Green nodes 
showed significant (P ≤ 0.05) decreased expression, and red nodes were significantly increased. The 
edges connecting TP53 to other genes represent published regulatory relationships: blue activating 
expression and orange inhibitory. The result indicates that although TP53 mRNA levels were not 










Figure 2. IL-6 treatment induced prostasphere formation in IL-6 nonexpressing PCa cell 
line cultures. (A) Effect of IL-6 treatment relative to vehicle control on the numbers of 
prostaspheres in 7-day cultures of MDA-PCa-2b cells. (B) Effect of IL-6 treatment (72-h) on 
viability of MDA-PCa-2b cells, run in triplicate and repeated twice. (C) Effect of IL-6 treatment 
relative to vehicle control on the numbers of prostaspheres in 7-day cultures of RC77T cells. (D) 
Effect of IL-6 on viability of RC77T cells, 7-day treatment run in triplicate and repeated twice. (E) 
Effect of 7-day IL-6 treatment on the numbers of PC3 prostaspheres. (F) Effect of IL-6 receptor 
inhibitor tocilizumab (10 lM, 7 days) on prostaspheres in PC3 cultures. (G) Impact of IL-6 
treatment on the percentage of CSCs in other cell lines in our panel measured by FACS analysis. 
Cells were treated with IL-6 at 10 ngmL1 for 7 or 14 days for RC77T. The fraction of CSCs 
relative to total cell count was measured based on CSC triple-marker-positive status (CD44+/
CD133+/EpCAM+). The results are presented as fold-change, IL-6 treated vs. control. 
Prostasphere assay and FACS data are representative of repeated experiments and are the 







Figure 3. Activation of IL-6 signaling upregulated expression of the MBD2 short isoform 
MBD2_v2 in PCa cell lines. (A) Immmunoblot analysis of MBD2 isoforms, phosphorylated STAT3 
(pSTAT3), and total STAT3 protein levels in IL-6 nonexpressing cell lines LNCaP and RC77T 
treated with IL-6 (10 ngmL1, 14 days) or diluent control. (B) MBD2_v2 mRNA levels in LnCaP and 
RC77T cell lines measured by real-time RT–PCR using TaqMan probes. Results are presented as 
fold-change, IL-6-treated relative to vehicle-treated conditions. (C) Immunoblot analysis of MBD2 
isoforms, pSTAT3, and total STAT3 protein in LNCaP cells treated with IL-6 in combination with the 
STAT3 inhibitor drug cryptotanshinone (CTS, 500 nM) or vehicle control for 14 days. (D) 
Immunoblot analysis of MBD2 isoforms, pSTAT3, and total STAT3 protein in IL-6-expressing cell 
line DU-145, treated with CTS (500 nM) or vehicle control for 48 h. Cell culture treatment, protein 
harvest, and immunoblot analysis were carried out three times. (E) Effect of CTS treatment relative 























































Figure 5. IL-6 treatment downregulated wild-type TP53 protein levels in non-IL-6 
expressing PCa cell lines.  (A) TP53 immunoblot analysis of IL-6 nonexpressing, TP53 
wild-type RC77T, and LNCaP cell lines, and TP53 mutant DU-145 cells, each treated with 
IL-6 or vehicle control for 7 days. (B) RT-PCR analysis of IL-6 nonexpressing, TP53 wild-
type RC77T, and LNCaP cell lines treated with IL-6 or vehicle control for 7 days. (C) RT–
PCR analysis of mRNA expression levels of known TP53-regulated genes in RC77T cells 
treated with IL-6 or vehicle control for 7 days. Cell culture treatment, protein harvest, and 




Figure 6. Summary of Conclusions. RNA-sequencing analysis of patient specimens 
and a systematic investigation of the role of exogenous and endogenous IL6 across a 
diverse prostate cancer cell line panel brings new understanding of IL6 expression 
patterns and signaling that drive prostate cancer stem cell-like cells, and underscores 
the potential importance of IL6 in PCa race disparities.
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CHAPTER 4: SUMMARY AND CONCLUSIONS  
4.1 Overview  
Obesity is an important risk factor for both TNBC and PCa. Others and we have 
shown that pro-inflammatory features associated with obesity, including upregulated 
production of ROS as well as leptin and insulin signaling, promotes CSCs and 
expression of pluripotency transcription factors [49-57]. What drives pluripotency 
transcription factor expression in these CSCs, downstream of these obesity-associated 
signaling pathways is still elusive. In our most recently published study from the Bollig-
Fischer lab, we discovered that we could inhibit TNBC CSCs by neutralizing ROS, a 
feature of obesity, in culture by treatment with hydrogen peroxide targeted antioxidants. 
For insights as to what genes might be impacted by antioxidant treatment, and 
regulating the CSC phenotype, we used a microarray approach to measure whole-
genome expression in antioxidant treated TNBC cell cultures. There we discovered that 
antioxidant treatment resulted in the downregulation of MBD2. Further we found that 
specific downregulation of the mRNA splicing variant MBD2_v2, was important for CSC 
self-renewal in vitro, and demonstrated that overexpression of MBD2_v2 promoted self-
renewal capacity of TNBC CSCs in culture, and was highly expressed in CSC versus 
bulk cancer cells	[57].  
Given that obesity is coupled with increased ROS, we hypothesized that obesity 
might fuel this mechanism to drive CSCs via MBD2_v2 expression. The work presented 
in this thesis addressed that hypothesis, associating MBD2_v2 expression with obesity 
in TNBC patients, and highlighting the importance of MBD2_v2 expression in promoting 
both TNBC and PCa CSCs. For example, we discovered that high MBD2_v2 tumor 
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gene expression is associated with worse outcomes and obesity in TNBC patients, and 
is relevant in high-grade PCa tumors. Moreover, we find a link between MBD2_v2 
expression and expansion of tumor-initiating CSCs with obesity in mice, and 
demonstrate that MBD2_v2, in addition to being ROS-sensitive, is also upregulated by 
the obesity-associated pro-inflammatory cytokine IL-6, which promotes PCa CSCs in a 
STAT3-dependent manner.  Finally, we show that similar to hPSCs	 [112], SRSF2-
mediated MBD2_v2 upregulation drives expression of pluripotency transcription factors, 
including NANOG (Fig. 1).  
Altogether these findings provide significant advancements in understanding of 
obesity-associated pro-inflammatory signaling and ROS, in driving TNBC and PCa 
CSCs through MBD2_v2. MBD2_v2 upregulation could likely be downstream of many of 
the already identified obesity-associated signaling pathways, which promote CSCs [49-
57]. Our studies indicate that MBD2_v2 upregulation is relevant in tumor initiating TNBC 
CSCs, linked to obesity, suggesting that targeting of MBD2_v2 could be clinically 
important in all TNBC, and more so in obese TNBC patients. Moreover, as we identified 
that MBD2_v2 regulates self-renewing CSCs and is specifically expressed in TNBC 
CSCs, our data suggest that MBD2_v2 could be useful as a functional CSC biomarker 
for research. Lastly, we find that similar to hPSCs	 [112], which require MBD2_v2 
regulated NANOG expression for pluripotency, MBD2_v2 also supports NANOG 
expression in CSCs; which is promoted by ROS-dependent expression of the SRSF2 
splicing factor. However the way in which ROS activates SRFS2, and how MBD2_v2 
regulates positive transcriptional regulation, needs to be further studied, in order to 
better understand the mechanistic function of MBD2_v2 versus MBD2_v1.  
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4.2 Clinical Implications 
 Within a primary tumor, the CSC niche both self-renews and asymmetrically 
divides, leading to growth of a heterogeneous population of cancer cells, and thus 
CSCs are intrinsically tumor forming. CSCs are also highly quiescent, providing inherent 
resistance to cytotoxic treatments, which target rapidly dividing tumors cells, associated 
with primary tumor reoccurrence	 [78]. However, dissemination of primary tumor cells to 
distant sites, through a process called metastasis, is the primary complication 
associated with cancer-related death; and studies show that as few as 0.1% of 
disseminated tumor cells may actually seed and subsequently have the ability to form 
macrometastases in a non-native tissue or organ [84]. CSCs, which are enriched in 
obese patients [49-57], are also associated with clinical cancer metastasis and support 
metastatic growth of tumors [58-71]. Therefore targeting CSCs could improve patient 
outcomes by preventing further metastatic growth of tumor cells and reoccurrence.  
 Based on the data collected in this study, we’ve uncovered several ways to 
potentially target CSCs.  In our studies we demonstrate that treatment with chemically-
derived antioxidants, such as (-) epicatechin, as well as engineered catalase biologics 
[57], can inhibit CSC growth by downregulating expression of SRSF2-MBD2_v2. In 
addition, we have demonstrated that the potent STAT3 inhibitor, cryptotanshinone 
(CTS), downregulates MBD2_v2 expression in PCa cell lines and also inhibits CSC 
growth. Finally, we realized the potential for IL-6 receptor inhibition, as the humanized 
anti-IL-6 antibody based biologic Tocilizumab, inhibited PCa CSC growth. Our pre-
clinical studies however were all performed in vitro. Testing the impact of STAT3 
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inhibitor, Tocilizumab, or antioxidant treatment on tumor forming CSCs in vivo, will be 
crucial for assessing the utility of these treatment approaches in patients. 
4.3 MBD2_v2 as an Functional CSC Biomarker 
  Cell surface markers, such as human CD44 molecule (CD44), CD133, and 
epithelial cell adhesion molecule (EpCAM), have been used to identify CSCs in BCa 
and PCa; in addition to the intracellular antigen aldehyde dehydrogenase 1 family 
member A1 (ALDH1). However these well-established CSC markers have yielded 
conflicting results, in that they do not correlate well with one another, and only a small 
percentage of some marker positive cell populations have been shown to be tumor 
forming.	[196, 197]. Significant overlap between identification of normal adult stem cells 
and CSCs is also an issue, such as CD133 in PCa [64, 198-204]. Moreover, the 
antibody-based techniques, which are used to identify CSCs in research and patient 
tumors, have a lot of issues with reproducibility	 [78]; which is underscored by even 
current reproducibility concerns with measurement of clinical BCa biomarkers by 
immunohistochemical staining	 [205]. In order to more accurately identify CSCs in 
research and in clinical patient specimens, there is still a great need for a CSC-specific 
biomarker, which can be detected by highly sensitive and more precise technologies. 
We find that MBD2_v2 expression is higher in CSC versus bulk cells in TNBC cultures	
[57], suggesting that MBD2_v2 could be a good candidate for development of a CSC-
specific functional biomarker.  
 Unlike other CSC markers, identification of MBD2_v2 would likely be performed 
by gene expression versus antibody-based assays, given its significant homology with 
other MBD family members, and nuclear localization	 [104]. Between MBD2 transcript 
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variants, there is only a short c-terminal end differentiating these two mRNA species, 
and MBD2 and MBD3 share significant homologies [104, 206]. However, in our studies 
we were able to use qRT-PCR, to very specifically measure MBD2_v2, using a Taqman 
Assay with exon spanning probes (Thermo Fisher Scientific, Assay ID: Hs00210557). 
This primer/probe based approach provides both specificity and reproducibility needed 
for research purposes as well as clinical testing, using as little as 1 ng RNA input.  
 In addition to a Taqman assay-based approach, we were able to associate 
MBD2_v2 expression in patient tumors with BMI, RFS, and GS from microarray 
datasets, which utilize splice variant specific probes. Unfortunately, we were not able to 
measure MBD2_v2 in PCa samples using RNA-seq, and this may be due to challenges 
associated with using RNA-seq to analyze specific mRNA splicing variants, which have 
been reported [195]. Although we were able to consistently detect and measure 
MBD2_v2 in patient samples, using microarray based technology, and in TNBC cell 
line-derived tumors and cultures with semi-quantitative RT-PCR, more research is 
needed to assess MBD2_v2 CSC-specificity in both TNBC and PCa.  Encouragingly, 
the specific expression of MBD2_v2 we identified in TNBC CSCs, could be paramount 







Figure 1. Summary and Conclusions. MBD2_v2 pathway extrapolated from mechanistic evidence in 
TNBC cell lines and tumors, as well as in PCa cell lines related to IL-6 signaling. Potential approaches for 




















CHAPTER 5: MATERIALS AND METHODS 
5.1 BCa cell lines and culture conditions. TNBC cell lines MDA-MB-468 and MDA-
MB-231 were acquired from the Biobanking and Correlative Sciences Core at KCI 
where they were passaged and authenticated by short tandem repeat (STR) analysis 
using the PowerPlex(r) 16 system (Promega, Madison, WI) immediately prior to use 
in this study. MDA-MB-468 and MDA-MB-231 cells were then cultured in 10% FBS 
DMEM media, at 37 °C, 5% CO2. SUM149 cells, developed by and acquired from Dr. 
Stephen Ethier [207], were cultured in 5% FBS HAM F-12 media containing 1 µg/ml 
hydrocortisone and 5 µg/mL human insulin, and authenticated by STR analysis using 
the PowerPlex(r) 16 System from Promega (Madison, WI).  
5.2 Immunoblot analysis. Immunoblot analysis was performed as we have done 
previously [57]. Briefly, protein lysates were harvested using NE-PER Nuclear and 
Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Waltham, MA, cat#78833) and 
concentrations measured by the Bradford assay. Protein samples (50 µg) were 
separated on a 10-12% SDS-PAGE gel in a Noxex XCell SureLock™ Mini-Cell 
Electrophoresis System (Invitrogen™, Waltham, MA) and transferred to a 
nitrocellulose membrane (GE Healthcare, Pittsburgh, PA) using Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA). Membranes were probed with 
primary antibodies following supplier recommendation and secondary peroxidase-
conjugated antibodies (anti-mouse or rabbit) from Vector Laboratories (Burlingame, 
CA). Primary antibodies targeting human MBD2 (Bethyl Laboratories, Montgomery, 
TX, cat#A301-633A-M), SRSF2 (Abcam, Cambridge, United Kingdom, 
cat#ab204916), TP53 (Thermo Fisher Scientific, Waltham, MA, cat#MS105P0); 
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STAT3 and pSTAT3 (Abcam, Cambridge, UK, cat#ab119352 and ab76315); and 
nucleoporin p62 (BD Biosciences, Franklin Lakes, NJ cat#610497).  
5.3 Semi-quantitative RT-PCR analysis. Real-time RT-PCR analysis was performed 
as previously by our lab [57, 208]. RNA was harvested from pulverized snap frozen 
tumors surgically excised from euthanized mice, or from cultured cell lines using the 
RNeasy mini kit from Qiagen (Valencia, CA). RNA samples derived from snap frozen 
tumors were further purified using the OneStep PCR Inhibitor Removal kit (Zymo 
Research, Irving, CA, cat#D6030), prior to RT-PCR. The High-Capacity RNA-to-cDNA 
Kit (Thermo Fisher Scientific, cat#4387406) was used to prepare cDNA. MBD2_v2, 
IL-6 and the ribosomal protein lateral stalk subunit P0 (RPLPO) TNBC reference or 
beta actin (β-Actin) PCa reference control genes were measured using TaqMan 
assay reagents (Fisher Scientific, cat#Hs00210557, Hs00985639, Hs99999902 and 
Hs99999903). PCR primers synthesized by IDT (Coralville, IA) and FastStart SYBR 
Green Master Mix (Roche, Indianapolis, IN) were used to analyze SRSF2, NANOG, 
CDKN1A, VCAN, EPHA2, SOX2, SOX9, (PrimerBank IDs [209]: 306482644c1, 
153945815c3, 310832423c2, 255918075c1, 296010835c1, 325651854c2, and 
182765453c1) and the β-Actin control gene (forward:CCCAGCACAATGAAGATCAA, 
reverse: ACATCTGCTGGAAGGTGGAC). For these experiments, 20 uL reactions 
were run in 96-well plates using 100-1000ng cDNA. Reactions were run in triplicate 
using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, 
CA). Relative expression was calculated by the ΔΔct method [210]. 
5.4 Mammosphere and Prostasphere formation assays. The presence and self-
renewal capacity of CSCs was examined in TNBC and PCa cell cultures by sphere-
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propagating assays, as described previously [57, 86]. Briefly, 1000 single cells were 
seeded in 1.5 mL of the FBS‐free sphere formation media (1:1 DMEM: F-12 media plus 
with B-27 and N-2 supplements, Gibco Brand, ThermoFisher, Waltham, MA, USA) in 
six-well Ultra Low Attachment plates (Corning Inc., Corning, NY, USA). Treatments 
were added and media replenished every 3 days. After 7 days of incubation, the 
mammospheres or prostaspheres (at a size equal or greater than 50 µm diameter) were 
counted and reported as a fraction of the total number of cells seeded. Images were 
taken using a Nikon Eclipse TE2000-U microscope (Tokyo, Japan). 
5.5 Animal work. All experiments using mice received prior approval from the WSU 
Institutional Animal Care and Use Committee. Sample size was arrived at empirically 
and was not predetermined by statistical methods. Female 5-week old B6.Rag1-/- 
mice were purchased from Jackson Laboratory (Bar Harbor, ME, cat#002216) and 
were acclimated for 1 week on standard chow diet. After 1 week, all mice were 
switched to and thereafter maintained on a purified diet. For experiments assessing 
tumor formation without consideration of DIO, mice were fed a control formula (kcal 
fat%=10, gram%=4.3) from Research Diets (New Brunswick, NJ, cat# D12450B). To 
study the effects of DIO, groups of mice were randomized to receive the control 
formula diet or a high-fat matched formula (kcal fat%=60, gram%=35, Research 
Diets, cat# D12492). At 11 weeks old, mice were aseptically inoculated with cancer 
cells, in the flank, subcutaneously by injection using a 1cc TB syringe with a 25g ½-inch 
needle, in a volume of 0.1-0.25 mL with matrigel (1:1 ratio). Resulting tumor mass (mg) 
was calculated based on caliper measurements (Tumor Mass = (lw2)/2). For 
assessing cell line tumor formation frequency mice were bilaterally inoculated 
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subcutaneously in the flank region (MDA-MB-231 left and MDA-MB-468 right) at 105, 
106 and 107 cell titers, 6 inoculations per cell line titer, with a total of 36 inoculations 
in 18 mice. In experiments assessing effects of DIO on tumor formation, mice were 
inoculated with MDA-MB-231 cells at 105, 106, and 107 cell titers (bilaterally), and with 
106 MDA-MB-468 cells (unilaterally). For these experiments there were 6 inoculations 
for MDA-MB-231 control groups (3 mice) for each titer and 8 inoculations in MDA-MB-
231 DIO groups (4 mice) for each titer (21 mice total). For the MDA-MB-468 cell line 
there were 6 inoculations per diet group (12 mice total). To compare MBD2_v2 
overexpressing and GFP-expressing MDA-MB-231 cell lines, mice were unilaterally 
inoculated with 105 cells, using 6 mice per cell line (12 total mice). To compare tumor 
formation by SRSF2 KD and non-silencing shRNA control MDA-MB-468 cells, DIO 
mice were unilaterally inoculated with 105 or 106 titers, using 6 mice per cell line per 
titer (24 mice total). 
5.6 Testing for associations between MBD2_v2 expression levels and patient 
outcomes and BMI. Association analysis was performed using the Kaplan-Meier 
Plotter database for BCa [211]. Associations between RFS and gene expression were 
determined for MBD2_v2 and SRSF2. Analysis was restricted to ERα-, PR- and 
HER2-negative tumors, i.e., TNBC. For MBD2_v2, the transcript-specific probe 
214396_s_at was used to query data combined from 5 datasets: E-MTAB-365, 
GSE19615, GSE21653, GSE2603, GSE31519. Auto select best cutoff and Censor at 
threshold options were selected. Quality control included removal of redundant samples 
and exclusion of outlier arrays.  The same parameters and combined data sets were 
used in analysis of SRSF2 expression using the probe 200753_x_at, identified as being 
66 
	
optimal by the JetSet best probe function [212]. Microarray gene expression data from a 
retrospective cohort of archived formalin fixed paraffin embedded tumors from African 
American women diagnosed with TNBC at the Karmanos Cancer Institute between 
2004-2010 were used to analyze the relationship between gene expression and BMI. 
Gene expression data were generated using the GeneChip™ Human Gene 2.1 ST 
Array after amplification of RNA using the Affymetrix WT Pico Kit (Affymetrix, Santa 
Clara, CA). Raw probe intensity data were normalized as implemented by the “rma” 
function in R to perform background subtraction, quantile normalization, and log2 
transformation. Probe sets were not summarized to allow analysis of alternative 
splice variants of our genes of interest. Linear regression analysis was performed, 
followed by a t-test (one-sided) to measure significance of the mean increase for 
MBD2_v2 expression in tumors from patients with BMI ≥ 30 (n=28) relative to BMI < 
30 (n=31). Methods conformed to the standards set by the Declaration of Helsinki and 
were reviewed by the Wayne State University Institutional Review Board.  
5.7 Genome-wide expression profiling of tumors harvested from mice. RNA was 
isolated from MDA-MB-468 cell line-derived tumors harvested from lean control mice 
(n=3) and DIO mice (n=3). Genome-wide expression was measured using the SurePrint 
G3 Human Gene Expression 8x60K Microarray and Low Input Quick Amp Labeling kits 
(Agilent Technologies, Santa Clara, CA). Arrays were scanned on the SureScan 
Microarray Scanner System. Data extraction was performed using Agilent Feature 
Extraction software. The "limma" package in R was used to perform normal-exponential 
convolution (with an offset of 50) background correction; loess normalization within 
arrays; and quantile normalization across arrays. The difference in gene expression (per 
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gene) was assessed by adjusting for multiple probes per gene, unequal variance within 
groups and correlated observations within the generalized least squares model 
framework. The resulting set of significant (P ≤ 0.05) differentially expressed genes 
(RefSeq coding IDs) were analyzed for further significance according to gene 
ontological (GO) enrichment analysis using DAVID [213] and ChEA 2016 using 
ENRICHR [181, 214]. The data set is available through Gene Expression Omnibus 
accession number GSE114604. 
5.8 RNA sequencing of patient samples. Specimen collection and analysis were 
carried out with the understanding and written consent of each subject. The study 
methodologies conformed to the standards set by the Declaration of Helsinki and were 
approved by the Wayne State University Institutional Review Board. RNA sequencing 
was applied to matched PCa and adjacent non-cancer prostate tissue specimens from 
16 patients, eight AAM and eight EAM, for a total of 32 samples. All PCa specimens 
represented an aggressive phenotype, with GS ≥ 7(4 + 3) [215]. De‐identified, FFPE 
high‐grade PCa (greater than 70% cancer cell content) and matched adjacent 
nonmalignant tissue samples were identified and reviewed at the Biorepository in the 
Department of Pathology at Wayne State University, Detroit, MI. Total RNA was isolated 
from the FFPE specimens (eight sections, 10 µm each per block; discarding surface 
section) using the Recover All kit for FFPE, with extended proteinase K and DNAse 
treatment (Life Technologies Inc., Carlsbad, CA, USA). RNA quantity and quality were 
estimated by spectrophotometry. Double‐stranded cDNA preparation and library 
construction were done with the Ovation Human FFPE RNA‐Sequencing Multiplex 
System (NuGEN, San Carlos, CA, USA) using 200 ng total RNA. Key features are as 
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follows: it is strand‐specific; no poly‐A selection step (or other selection step that could 
introduce bias or be problematic for degraded RNA); and the approach integrates an 
insert dependent adapter cleavage step that specifically targets ribosomal RNA for 
degradation [216]. Quality of library preparations was assessed using the Tapestation 
(Agilent, Santa Clara, CA, USA). Cluster generation was performed using the Illumina 
cBot and HiSeq Paired End Cluster Generation Kit (Illumina, San Diego, CA, USA). 
Flow cells were paired end sequenced (100 cycles) on an Illumina HiSeq 2500 (high‐
output mode). Sample libraries were indexed and multiplexed in randomized fashion: 
four per lane of an 8‐lane flow cell. FastQC analysis 
(www.bioinformatics.babraham.ac.uk/) was done to know that more than 85% of reads, 
for all samples, passed QC30. Transcript and gene‐level expression abundances were 
calculated using the cufflinks2 module from the Cufflinks2 Suite [217, 218]. The 
abundance results were reported in plain text files showing P‐values (adjusted for 
multiple testing) and normalized abundance data in terms of FPKM (fragments per 
kilobase of transcript per million mapped reads). 
In an additional quality control step, we ran a test of the nonparametric 
Spearman correlation between identical samples sequenced twice, in different batches, 
which demonstrated high reproducibility (98%, data not shown). We also compared our 
RNA‐sequencing data with expression data from our published study that employed 
microarray‐based analysis [128]. Applying nonparametric Spearman correlation analysis 
to measurements from the two technologies yielded a high correlation (0.805 AAM and 
0.811 EAM), signifying that the results of high‐throughput sequencing compared to gene 
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expression measured by validated microarray analysis across the bulk of genes 
analyzed by both methods, even though the PCa samples studied were different. 
5.9 Statistical analysis of RNA sequencing data. Matched high‐grade [GS ≥ 7(4 + 3)] 
prostate tumor and adjacent normal specimens from 16 patients (eight AAM and eight 
EAM) were subjected to two replicate runs of RNA‐sequencing analyses. The standard 
FPKM per transcript were normalized by adding 1 and applying a log‐transformation. A 
mixed model analysis was used to model normalized read count as a function of race, 
tissue type (tumor or normal), and their interaction for each transcript, accounting for the 
correlation between replicates and different variance in the two batches. The outcomes 
identified transcripts with a significant (P ≤ 0.05) interaction effect between race and 
tissue type. FASTQ and processed data are available at Gene Expression Omnibus 
GSE104131. The Enrichr tool [181] was applied to the resulting significant gene list to 
identify significantly overrepresented KEGG pathways (P ≤ 0.05). The Upstream 
Regulator analysis tool [182] included in the Ingenuity Systems (Qiagen, Redwood City, 
CA, USA) software suite, was used to identify significant overenrichment (P ≤ 0.05) for 
subsets of genes associated with activation or inactivation of upstream regulators.  
5.10 PCa cell lines and culture conditions. The established PCa cell line MDA-
PCa-2b was newly purchased from ATCC  (Manassas, VA) for this study. The 
established cell lines LNCaP, PC3 and DU-145 were acquired from the Biobanking 
and Correlative Sciences Core at KCI where they were passaged and authenticated 
by STR analysis using the PowerPlex(r) 16 system (Promega, Madison, WI) 
immediately prior to use in this study. RC77T PCa cell line was established and 
provided to us by Dr. Clayton Yates [219]. LNCaP, PC3 and DU-145 cells were 
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maintained in 10% FBS RPMI-1640 media containing 50 µg /mL gentamycin at 37 °C, 
5% CO2. RC77T cells were seeded on plates coated with FNC Coating Mix™ 
(ATHENA, Baltimore, MD, cat#0407) in Gibco keratinocyte-SFM media (Thermo 
Fisher, Waltham, MA, cat#10724-011), supplemented with EGF and BPE, with 2% 
FBS immediately added to each plate after splitting. FBS containing media was 
replaced by keratinocyte-SFM media, supplemented with EGF and BPE, 24 hrs after 
splitting or seeding and RC77T cells were maintained at 37 °C, 5% CO2. MDA-PCa-
2B cells were maintained in 10% FBS F-12K media (Corning Inc., Corning, NY, 
cat#10-025-cv,) containing 1% penicillin/streptomycin supplemented with 25 ng/mL 
cholera toxin, 10 ng/mL EGF, 0.005 mM phospho-ethanolamine, 100 pg/mL 
hydrocortisone, 45 nm selenious acid at 37 °C, 5% CO2.   
5.11 PCa cell line treatments. IL-6 was purchased from BD Biosciences (Franklin 
Lakes, NJ). STAT3 inhibitor CTS was purchased from Sigma-Aldrich (St. Louis, MO, 
cat# C5624-5MG). The IL-6 receptor inhibitor drug, Tocilizumab (Genentech, South 
San Francisco, CA), was from the Karmanos Cancer Institute pharmacy. See results 
and figures for all concentrations and treatment times used in each experiment.  
5.12 Viability Assays. For viability assay, cells were seeded at 3000 cells/well in 96-
well plates, and incubated at 37 °C, 5% CO2 for 24 hrs. Cells were then treated with 0.5 
ng/mL, 10 ng/mL or no IL-6 from BD Biosciences (Franklin Lakes, NJ), and incubated 
for 7 days at 37 °C, 5% CO2. Following IL-6 treatment, MTT assays or ATP assays 
were performed using the CellTiter-Glo® Luminescent Cell Viability (Promega, Madison, 
WI, cat#G7571) or Vybrant® MTT Cell Proliferation (Life technologies, Carlsbad, CA, 
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cat#V13154) Assay Kits, respectively. Cell viability is shown as percentage (%), 
comparing mean cell viability for IL-6 treated to non-treated negative control samples. 
5.13 FACS analysis. CSCs and total PCa cells were counted by FACs analysis, using 
the BD LSR II (BD Biosciences, San Jose, CA, USA), at the Karmanos Cancer Institute 
Microscopy, Imaging and Cytometry Resources Core. CSCs were sorted based on 
triple-marker (CD44+/CD133+/EpCAM+) positive status. Fluorochrome-labeled 
monoclonal antibodies against human CD44, CD133, and EpCAM proteins were 
obtained from EBiosciences (San Diego, CA, USA; cat#25-0441-82), Miltenyil Biotec 
(Cologne, Germany, cat#130-090-854), and BD Biosciences Franklin Lakes, NJ, USA, 
cat#347198), respectively. 
5.14 Stable MBD2_v2 overexpression in PCa cell lines. Packaged lentiviral particles 
to overexpress GFP or mCherry control genes, or MBD2_v2 were purchased from 
Cyagen Biosciences (Santa Clara, CA, USA). The custom‐synthesized human 
MBD2_v2 (NM015832.4) gene, mCherry, or GFP sequence were subcloned into a 
lentiviral expression vector downstream of the cytomegalovirus (CMV) promoter. The 
construct was sequenced to ensure that the MBD2_v2 sequence and orientation were 
correct. The expression vector also expressed a puromycin resistance gene. Cells were 
transduced and selected with puromycin. GFP expression was visible by fluorescence 
microscopy. Overexpression of MBD2_v2 was validated by immunoblot analysis and 
semi-quantitative RT–PCR using TaqMan probes. 
5.15 Meta‐analysis of MBD2_v2 expression using the Oncomine database. 
Microarray data from the Oncomine database was accessed on May 22, 2017 [188]. All 
PCa datasets utilizing the splice variant‐specific Affymetrix probe for MBD2_v2 
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(214396_s_at) or MBD2_v1 (202484_s_at), were queried to obtain log2 median-
centered intensities, based on GS for clinical specimens only. Patient specimens (n = 
244) from a total of five studies [220-224], were partitioned into two groups representing 
low‐grade and high‐grade PCa (GS 4-7 and GS 8-9). A two-sided unpaired t-test was 
performed on log2 median-centered intensities to compare the two groups. 
5.16 Stable SRSF2 KD and MBD2_v2 overexpression in TNBC cell lines. Stable 
overexpression of MBD2_v2 in MDA-MB-231 cells was performed as done by us 
previously [57]. Packaged lentiviral particles to overexpress MBD2_v2 (NM015832.4) 
or GFP were purchased from Cyagen Biosciences (Santa Clara, CA). Stable lentiviral-
mediated shRNA KD of SRSF2 expression was performed, as previously described, 
using the Open Biosystems Expression Arrest GIPZ lentiviral shRNAmir system [225]. 
MDA-MB-468 cells were transduced with vectors targeting SRSF2 (cat#RHS4430-
98485060 and RHS4430-101104677) or the non-silencing control vector.  
5.20 Statistical analyses. Statistical analyses were performed using R 3.3.2. Graphs 
were generated with R 3.3.2 or GraphPad Prism. P values ≤ 0.05 are reported as 
significant. Welch’s t-test was applied to semi-quantitative RT-PCR and 
mammosphere assay data. Gray’s test of difference in cumulative incidence was 
used to assess the significance of differences observed in mouse tumor formation 
frequency and time to event between experimental groups. Fisher’s exact test was 
used to assess the difference in tumor frequency on a given date. Generalized least 
squares (GLS), allowing for correlated observations in the same animal when 
appropriate (i.e., bilateral inoculation) and unequal variation between titers, was used 
to model log tumor mass. The P-value for the interaction between group and time 
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was utilized to test whether the rate of growth, once a tumor has formed, is different 
between the groups under study. Doubling time was estimated per animal using GLS 
(to allow for correlated observations) and differences in estimated doubling times 
between groups were assessed by Welch’s t-test.  
Statistical analysis of data resulting from experiments using PCa cell lines was 
performed using Graphpad Prism (GraphPad Software Inc., La Jolla, CA, USA). Semi 
quantitative RT–PCR data are presented as the mean and standard deviation of a 
representative experiment. Mann–Whitney U test or unpaired two‐sided t‐test (Welch's t‐
test) was performed to test the significance of difference between two groups, a P‐value 










Figure S1. Full-length scanned images of immunoblot film. Panels here 
correspond to cropped bands in:  (a) Fig. 3b,  (b) Fig. 4b top,  (c) Fig. 4b lower, and 
(d) Fig. 4c. Protein ladders were used to estimate molecular weight in kilodaltons 
and are represented at the left of each panel. The antibody-targeted protein is 












 Figure S2. Testing for associations between TNBC tumor expression of 
full-length MBD2 isoform MBD2_v1 and patient outcomes and BMI. (A) 
Analysis was performed with the online KM Plotter database,using  a logrank 
test of association between relapse-free survival and MBD2_v1 transcript level. 
The number of subjects at risk at different time points is indicated below the x-
axis (B)Testing for transcript level associations with BMI, was done using a 
separate gene expression microarray dataset generated from TNBC 
specimens (n=59) collected at the Karmanos Cancer Institute, Detroit, MI, 
where BMI data corresponding to deidentified samples was available. The 
association between BMI and MBD2_v1expression was tested using linear 
regression analysis (P>0.05, not significant).
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Figure S3. MBD2_v2 expression in TNBC cell line cultures prior 
to mouse inoculation. (a) Comparison of MBD2_v2 expression 
levels in MDA-MB-468 and MDA-MB-231 cell cultures by semi-













Figure S5. Effect of (–) epicatechin antioxidant treatment on ROS and MBD2_v2 
levels in TNBC cell cultures. (A) The effectiveness of the (–)-epicatechin preparation to 
decrease hydrogen peroxide levels were confirmed using MDA-MB-468 cells, with 48 hour 
20µM treatment, and the MAK164 Intracellular hydrogen peroxide assay (Sigma-Aldrich). 
Results are the mean of 3 independent experiments ± s.e.m.  (B). The effect of (-)-
epicatechin (Epi) antioxdiant treatment (48hours,120µM) on MBD2_v2 mRNA  (mean fold 
change for sets of 3 technical replicates) and (C) protein expression levels in MDA-MB-468 
and SUM149 TNBC cell lines. Immunoblots are representative of 2 independent 
experiments for each cell line. 
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Figure S4. MBD2_v2 overexpressing and GFP expressing tumor 
growth curves.Growth curves for tumors formed by MBD2_v2 
overexpressing and GFP expressing control MDA-MB-231 cells in 
mice on the control formula diet. Tumor mass was plotted for each 
tumor over the course of the 150 day experiment and modeled 
growth curves (bold) are superimposed. A generalized least squares 









Figure S6. SRSF2 knockdown tumor levels and growth curves, and patient tumor 
SRSF2 expression related to BMI. (a) SRSF2 knockdown and non-silencing MDA-
MB-468 cell line-derived tumor growth curves. Tumor mass was plotted for each tumor 
over the course of the 150 day experiment and modeled growth curves (bold) are 
superimposed. A generalized least squares test was used to calculate a P value (P >0.05). 
(b) SRSF2 levels in tumors formed by SRSF2 knockdown and nonsilencing vector control 
MDA-MB-468 cells harvested from DIO mice (assessed by semiquantitative RTPCR 
analysis).  (c) Graph of patient tumor SRSF2 transcript expression and relationship with 
BMI (KCI dataset). 2 of 2 translated variants (NCBI Refseq IDs) are plotted. There is no 













Figure S7. Visceral adiposity, oxidative stress levels and enrichment of signaling pathway 
genes in tumors comparing DIO and control mice. (a) Representative DIO specimen exhibiting 
increased visceral adiposity relative to lean control mouse. These examples were humanly 
euthanized when tumor burden end-point was reached 100 days post inoculation. (b) Liver 
malondialdehyde (MDA) levels (an indicator of systemic oxidative stress) in DIO and control mice (6 
randomly selected per group). (c) Tumor signaling pathways impacted by DIO. Genome-wide 
expression analysis was performed to compare MDA-MB-468 tumors harvested from DIO mice 
(n=3, randomly selected) with those harvested from lean control mice (n=3). The Enrichr tool and 
NCI-Nature Pathways library were applied to the significant differentially expressed gene set (P < 
0.01) to identify significantly over-represented signaling pathways. The P value of overlap and top 







Figure S8. NANOG in TNBC cell line cultures and tumors. (A) NANOG 
gene expression in cultures of MBD2_v2 overexpressing MDA-MB-468 cells 
compared to GFP expressing controls, by semi-quantitative RT-PCR analysis 
(P<0.001,Welch’s t-test). Bars, ±s.d. for 3 technical replicates. (B) 
Comparison of NANOG expression in MDA-MB-468 tumors harvested from 
DIO (n=3) and control (n=3) mice by semi-quantitative RT-PCR analysis 
(P<0.01,Welch’s t-test). Bars, ±s.e.m. NANOG was similarly observed to be 






Supplementary Figure S1. (Left panel) Quantity and quality of RNA isolated from FFPE samples
was estimated by spectrophotometry analysis using the Trinean DropSense (PerkinElmer, Waltham,
MA). (Right panel) The state of each sample library preparation was assed prior to sequencing using
the TapeStation (Agilent, Santa Clara, CA). Here the quality in library preparation is demonstrated by
the consistency in fragment size and appropriate yield. Lane order, starting top left lane 2, correspond
to listing in left panel.
2200 TapeStation Software (A.01.03) 
Controller Notes 
Bollig-Fischer.  Nugen FFPE RNA libraries. 1ul product run. 
Gel Image 
High Sensitivity D1K ScreenTape® 
Figure S1. (Leftpanel) Quantity and quality of RNA isolated from FFPE samples was 
estimated by spe troph tometry analysis using the Trinean Drop Sense 
(PerkinElmer,W ltham,MA). (Rightpanel) The state of each sampl  lib a y pr parat on was 
assessed prior to sequencing using the TapeStation (Agilent,SantaClara,CA). Here the quality 
in library preparation is demonstrated by the consistency in fragment size and appropriate 




Figure S2. Comparison ofmean values for log (base 10) FPKM read counts from RNA-
sequencinganalysis and mean expression values from DASL microarray analysis.Sequencing data 
represents 16 PCa specimens from 8 African American (AA) men and 8 European American (EA) men, all 
with Gleason score (GS)≥7(4+3). DASL gene expression data is accessible via Gene Expression Omnibus 
GSE41969 and represents95 AA and 134 EA PCa specimens. The sample sets were non-overlapping and 
analysis was limited to genes measured by the microarray (n=512). A test of non-parametric (Spearman) 
correlation between measurementsfrom the two technologies yields a correlation of 0.805 for AA men and 




Figure S3. Top 9 most significant differentially expressed genes (p<0.05), based on 





Figure S4. Additional representative images demonstrating the effect of stable MBD2_v2 
overexpression in LNCaP and RC77T cells on prostasphere size relative to GFP or mCherry 




Patient No. Race Grade 
1 AA 8 
2 AA 8 
3 AA 9 
4 AA 9 
5 AA 8 
6 AA 9 
7 AA 8 
8 AA 8 
9 C 7 (4+3) 
10 C 7 (4+3) 
11 C 7 (4+3) 
12 C 7 (4+3) 
13 C 8 
14 C 8 
15 C 7 (4+3) 
16 C 7 (4+3) 
Supplementary Table S1. Gleason Score/Grade for each PCa sample used 
in RNA-sequencing analysis. RNA sequencing was performed on matched 
high grade [GS≥7(4+3)] prostate tumor and adjacent nonmalignant specimens 




Supplementary Table S2. The Enrichr tool was used to identify significantly over-represented 
KEGG pathways in the results of RNA-sequencing data differential analysis comparing tumor 
versus normal gene expression as a function of race. Genes from our analyzed dataset that are 
within each significant pathway are listed, including cytokines IL6 and TGFB1.  
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Supplementary Table S3. FACS data collected for IL6-treated and non-treated PCa cell lines 
with sorting of the cancer stem-like cell fraction based on positive status of three surface 
markers, CD44, CD133, and EPCAM. Based on analysis of 3 independent replicates, the 
values under the Mean Percentage (%) column represent the triple marker-positive cell 
population fraction of the mean total live cell count.  For each cell line, fold-change represents 
the percentage of triple marker positive cells in IL6 treated cultures relative to the percentage in 






Cell Count  




Change  SEM p-value 
LNCaP IL6 519923 3.718 3.3 0.5115 0.02 
Control 1054734 1.132 1.0 0.2710 
RC77T IL6 505971 0.012 2.5 0.0015 0.02 
Control 671333 0.005 1.0 0.0007 
PC3 IL6 490014 0.059 1.6 0.0238 0.93 
Control 449287 0.037 1.0 0.0144 
DU-145 IL6 600000 0.029 1.1 0.0087 0.97 
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Obesity is a risk factor for both TNBC and PCa, and pro-inflammatory 
features associated with obesity, including upregulated production of ROS, 
promote CSCs. Previously published work from the Bollig-Fischer laboratory 
established that TNBC CSCs could be inhibited by neutralizing ROS in culture 
with H2O2 targeted antioxidants. In this report, antioxidant treatment resulted in 
the downregulation of mRNA splicing variant MBD2_v2. MBD2_v2 was highly 
expressed in CSCs versus bulk TNBC cells and supported self-renewal in vitro.  
As obesity is coupled with increased ROS, we hypothesized that obesity 
could drive CSCs via MBD2_v2 expression. The work presented in this thesis 
addressed this hypothesis, linking MBD2_v2 expression to obesity in TNBC 
patients, and demonstrating the importance of SRSF2-MBD2_v2 mediated 
expression of pluripotency transcription factors in driving tumor-initiating TNBC 
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